CUMULATIVE SUPPLEMENT 8
JAN'97-AUG'97



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 8

AUGUST 1997

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 1997

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP PHARMACEUTICALS DIV (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA PHARMACEUTICAL CO DIV CIBA GEIGY CORP (CIBA)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA SELF MEDICATION INC DIV CIBA GEIGY CORP (CIBA)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
CIBA VISION OPHTHALMICS DIV CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
FERRING LABORATORIES INC (FERRING)	FERRING PHARMACEUTICALS INC (FERRING)
GEIGY PHARMACEUTICALS DIV CIBA GEIGY CORP (GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
LEMMON CO SUB TAG PHARMACEUTICAL INC (LEMMON)	BIOCRAFT LABORATORIES INC (BIOCRAFT) **THEN CHANGED TO** TEVA PHARMACEUTICALS USA (TEVA)
SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS (SANDOZ)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INC (SANDOZ)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
SANDOZ RESEARCH INSTITUTE INC (SANDOZ)	NOVARTIS PHARMACEUTCALS CORP (NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SANOFI WINTHROP INC (SANOFI WINTHROP)	SANOFI PHARMACEUTICAL INC (SANOFI)
SURVIVAL TECHNOLOGY INC (SURVIVAL TECH)	MERIDIAN MEDICAL TECHNOLOGIES INC (MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novapharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1996*	MAR 1997	JUN 1997	SEP 1997
DRUG PRODUCTS LISTED	9392	9493	9533	
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)	2388 (25.0%)	
MULTISOURCE	6905 (73.5%)	6991 (73.7%)	7031 (73.8%)	
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)	6626 (69.5%)	
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)	405 (4.3%)	
EXCEPTIONS[1]	104 (1.1%)	115 (1.2%)	114 (1.2%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	8	
NUMBER OF APPLICANTS	650	662	682	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER 25MG N20482 004 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE

AB	GRAHAM DM	**325MG;50MG;40MG**	**N88743 001**	**JUL 18, 1985**
AB		**325MG;50MG;40MG**	**N88765 001**	**MAR 27, 1985**
AB		**325MG;50MG;40MG**	**N89067 001**	**APR 19, 1985**
@		325MG;50MG;40MG	N88743 001	JUL 18, 1985
@		325MG;50MG;40MG	N88765 001	MAR 27, 1985
@		325MG;50MG;40MG	N89067 001	APR 19, 1985

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

> ADD > **AA**	MIKART	**356.4MG;30MG;16MG**	**N40109 001**	**AUG 26, 1997**
DHC PLUS				
> ADD > **AA** +	PURDUE FREDERICK	**356.4MG;30MG;16MG**	**N88584 001**	**MAR 04, 1986**

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

> ADD >	@ BARR	500MG;5MG	N88577 001	DEC 21, 1984
AA	EON	**500MG;5MG**	**N40149 001**	**JAN 27, 1997**
AA		**750MG;7.5MG**	**N40149 002**	**JAN 27, 1997**
> ADD > **AA**	PEACHTREE	**500MG;10MG**	**N40210 001**	**AUG 13, 1997**

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	VINTAGE PHARMS	**500MG;2.5MG**	**N40144 002**	**APR 25, 1997**
AA		**650MG;7.5MG**	**N40155 001**	**APR 14, 1997**
AA	WATSON LABS	**500MG;10MG**	**N40148 002**	**FEB 14, 1997**

> DLT > **HYDROCODONE BITARTRATE W/ ACETAMINOPHEN**

> DLT > **AA**	BARR	**500MG;5MG**	**N88577 001**	**DEC 21, 1984**
LORTAB				
AA +	GRAHAM DM	**500MG;10MG**	**N40100 001**	**JAN 26, 1996**
AA +	UCB	**500MG;10MG**	N40100 001	JAN 26, 1996
		325MG;5MG	N40099 001	JUN 25, 1997
NORCO				
+	WATSON LABS	325MG;10MG	N40148 001	FEB 14, 1997

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	VINTAGE PHARMS	**650MG;100MG**	**N74843 001**	**FEB 12, 1997**

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB	TARO	**125MG**	**N40195 001**	**MAY 28, 1997**
AB		**250MG**	**N40195 002**	**MAY 28, 1997**

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

> ADD > **AP**	ABBOTT	**EQ 500MG BASE/VIAL**	**N40108 001**	**OCT 30, 1995**

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

>DLT> >DLT	AP	SANOFI WINTHROP	EQ 500MG BASE/VIAL	N40108 001 OCT 30, 1995	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC
TRIDESILON

	BAYER	2%;0.05%	N17914 001	
	@	2%;0.05%	N17914 001	

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	AESGEN	200MG	N74833 001 APR 22, 1997	
AB	ESI LEDERLE	200MG	N74872 001 APR 22, 1997	
AB	LEK PHARM	200MG	N74750 001 APR 22, 1997	
AB	LEMMON	200MG	N74828 001 APR 22, 1997	
AB	MYLAN	200MG	N74727 001 APR 22, 1997	
AB	NOVOPHARM	200MG	N74578 001 APR 22, 1997	
>ADD> >ADD> AB	PUREPAC PHARM	200MG	N74906 001 AUG 26, 1997	
AB	ROXANE	200MG	N74570 002 APR 22, 1997	
AB	TEVA	200MG	N74828 001 APR 22, 1997	
AB	ZENITH GOLDLINE	200MG	N74674 001 APR 22, 1997	
	ZOVIRAX			
AB +	GLAXO WELLCOME	200MG	N18828 001 JAN 25, 1985	

SUSPENSION; ORAL
ACYCLOVIR

AB	ALPHARMA	200MG/5ML	N74738 001 APR 28, 1997	

ACYCLOVIR

SUSPENSION; ORAL
ZOVIRAX

AB +	GLAXO WELLCOME	200MG/5ML	N19909 001 DEC 22, 1989	

TABLET; ORAL
ACYCLOVIR

AB	ESI LEDERLE	400MG	N74834 001 APR 24, 1997	
AB		800MG	N74834 002 APR 24, 1997	
AB	LEK PHARM	400MG	N74658 001 APR 22, 1997	
AB		800MG	N74658 002 APR 22, 1997	
AB	NOVOPHARM	400MG	N74556 002 APR 22, 1997	
AB		800MG	N74556 003 APR 22, 1997	
+		200MG	N74556 001 APR 22, 1997	
AB	PUREPAC PHARM	400MG	N74870 001 JUN 05, 1997	
AB		800MG	N74870 002 JUN 05, 1997	
AB	ZENITH GOLDLINE	400MG	N74836 001 APR 22, 1997	
AB		800MG	N74836 002 APR 22, 1997	
	ZOVIRAX			
AB	GLAXO WELLCOME	400MG	N20089 001 APR 30, 1991	
AB +		800MG	N20089 002 APR 30, 1991	

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

>ADD> >ADD> AP	ABBOTT	EQ 500MG BASE/VIAL	N74663 001 APR 22, 1997	
AP		EQ 500MG BASE/VIAL	N74758 001 APR 22, 1997	
>ADD> >ADD> AP		EQ 1GM BASE/VIAL	N74663 002 APR 22, 1997	

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	ABBOTT	EQ 1GM BASE/VIAL	N74758 002	APR 22, 1997
AP	BEDFORD	EQ 500MG BASE/VIAL	N74596 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74596 001	APR 22, 1997
AP +	FAULDING	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
> ADD > AP	GENSIA	EQ 500MG BASE/VIAL	N74969 001	AUG 26, 1997
> ADD > AP		EQ 1GM BASE/VIAL	N74969 002	AUG 26, 1997
> DLT > AP	SANOFI	EQ 500MG BASE/VIAL	N74663 001	APR 22, 1997
> DLT > AP		EQ 1GM BASE/VIAL	N74663 002	APR 22, 1997

ZOVIRAX

AP +	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N18603 001	OCT 22, 1982
AP +		EQ 1GM BASE/VIAL	N18603 002	JUN 29, 1989

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

> ADD > AB	ALPHARMA	0.09MG/INH	N73045 001	AUG 19, 1997

ALENDRONATE SODIUM

TABLET; ORAL

FOSAMAX

	MERCK	EQ 5MG BASE	N20560 003	APR 25, 1997

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	ROYCE LABS	0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

AP	PHARMACIA AND UPJOHN	0.005MG/VIAL	N20379 003	JUN 27, 1996
AP		0.01MG/VIAL	N20379 001	JUL 06, 1995
AP		0.02MG/VIAL	N20379 002	JUL 06, 1995
AP +		0.04MG/VIAL	N20379 004	MAY 19, 1997

EDEX

AP	SCHWARZ PHARMA	0.005MG/VIAL	N20649 001	JUN 12, 1997
AP		0.01MG/VIAL	N20649 002	JUN 12, 1997
AP		0.02MG/VIAL	N20649 003	JUN 12, 1997
AP +		0.04MG/VIAL	N20649 004	JUN 12, 1997

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

> ADD > AP	ABBOTT	EQ 250MG BASE/ML	N64098 001	JUN 26, 1995
> ADD > AP		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995
AP	ELKINS SINN	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
@		EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
> DLT > AP	SANOFI WINTHROP	EQ 250MG BASE/ML	N64098 001	JUN 26, 1995
> DLT > AP		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABBOTT	EQ 500MG BASE/100ML	N64146 001 APR 02, 1997

AMINO ACIDS

INJECTABLE; INJECTION

	AMINOSYN II 5%		
	ABBOTT	5%	N19438 002 APR 03, 1986
@		5%	N19438 002 APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

	ABBOTT	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988
@		5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 002 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 005 MAR 26, 1997
	CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 001 MAR 26, 1997
	CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 009 MAR 26, 1997
	CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 011 MAR 26, 1997
	CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 012 MAR 26, 1997
	CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 008 MAR 26, 1997
	CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML	N20678 016 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE — 5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE — 5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE — 5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 019 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE — 5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 021 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

> DLT > > DLT > > ADD > > ADD >
ABBOTT — 3.5%;25GM/100ML — N19505 002 NOV 07, 1986

@ — 3.5%;25GM/100ML — N19505 002 NOV 07, 1986

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

> DLT > > DLT > > ADD > > ADD >
ABBOTT — 4.25%;25GM/100ML — N19504 002 NOV 07, 1986

@ — 4.25%;25GM/100ML — N19504 002 NOV 07, 1986

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

AP + SEARLE — 25MG/ML — N87243 001 MAY 24, 1982

@ — 25MG/ML — N87243 001 MAY 24, 1982

AMINOPHYLLINE

AP ELKINS SINN — 25MG/ML — N87239 001
AP + — 25MG/ML — N87239 001
AP PHARMA SERVE NY — 25MG/ML — N87387 001 JUN 03, 1983

@ — 25MG/ML — N87387 001 JUN 03, 1983

TABLET; ORAL

AMINOPHYLLINE

BD HALSEY — 100MG — N84674 001

@ — 100MG — N84674 001

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

+ PURDUE FREDERICK — 225MG — N86760 001

@ — 225MG — N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

BP HALSEY — 10MG — N85923 001
BP — 50MG — N85925 001
BP — 75MG — N85926 001 MAY 20, 1983
BP — 100MG — N85927 001 MAY 20, 1983

@ — 10MG — N85923 001
@ — 50MG — N85925 001
@ — 75MG — N85926 001 MAY 20, 1983
@ — 100MG — N85927 001 MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

> ADD > AB ICN — EQ 12.5MG BASE;5MG — N16949 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

		LIMBITROL				
> DLT >	AB	ROCHE	EQ 12.5MG BASE;5MG	N16949 001		
		LIMBITROL DS				
> ADD >	AB	+ ICN	EQ 25MG BASE;10MG	N16949 002		
> DLT >	AB	+ ROCHE	EQ 25MG BASE;10MG	N16949 002		

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	ETRAFON-A			
BP	SCHERING	10MG;4MG	N14713 002	
	@	10MG;4MG	N14713 002	

AMOXICILLIN

CAPSULE; ORAL

	AMOXIL			
AB	+ SMITHKLINE BEECHAM	250MG	N50459 001	
AB		250MG	N62216 001	
AB	+	250MG	N62216 001	
AB	+	500MG	N50459 002	
AB		500MG	N62216 004	
AB	+	500MG	N62216 004	
	@	250MG	N50459 001	
	@	500MG	N50459 002	

POWDER FOR RECONSTITUTION; ORAL

	AMOXIL			
AB	+ SMITHKLINE BEECHAM	125MG/5ML	N50460 001	
AB		125MG/5ML	N62226 001	
AB	+	125MG/5ML	N62226 001	
AB	+	250MG/5ML	N50460 002	
AB	+	50MG/ML	N50460 005	
AB		250MG/5ML	N62226 002	
AB	+	250MG/5ML	N62226 002	
AB		50MG/ML	N62226 005	
AB	+	50MG/ML	N62226 005	
	@	125MG/5ML	N50460 001	
	@	250MG/5ML	N50460 002	
	@	50MG/ML	N50460 005	
	LAROTID			
AB	SMITHKLINE BEECHAM	50MG/ML	N50460 006	
	@	50MG/ML	N50460 006	

AMPHOTERICIN B

INJECTABLE; INJECTION

	AMPHOTERICIN B			
> ADD > AP	ABBOTT	50MG/VIAL	N64141 001	
> ADD >			DEC 23, 1996	
AP	SANOFI WINTHROP	50MG/VIAL	N64141 001	
> DLT >			DEC 23, 1996	

INJECTABLE, LIPOSOMAL; INJECTION

> ADD >	AMBISOME		
> ADD >	+ FUJISAWA	50MG/VIAL	N50740 001
> ADD >			AUG 11, 1997

OINTMENT; TOPICAL

	FUNGIZONE		
	+ APOTHECON	3%	N50313 001
	@	3%	N50313 001

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

	AGRYLIN		
	ROBERTS LABS	EQ 0.5MG BASE	N20333 001
			MAR 14, 1997
	+	EQ 1MG BASE	N20333 002
			MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

	NORMIFLO		
	+ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002
			MAY 23, 1997
	+	10,000 UNITS/0.5ML	N20227 001
			MAY 23, 1997

ASPIRIN; BUTALBITAL

TABLET; ORAL

	AXOTAL		
	+ SAVAGE LABS	650MG;50MG	N88305 001
			OCT 13, 1983
	@	650MG;50MG	N88305 001
			OCT 13, 1983

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

	CODOXY			
AA	HALSEY	325MG;4.5MG;0.38MG	N87464 001 JUL 01, 1982	
	@	325MG;4.5MG;0.38MG	N87464 001 JUL 01, 1982	

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	MUTUAL PHARM	25MG	N74499 001 JUL 30, 1997	
AB	SIDMAK LABS NJ	25MG	N74101 001 JUL 17, 1997	
AB		50MG	N74101 002 JUL 17, 1997	
AB		100MG	N74101 003 JUL 17, 1997	

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

	ATRACURIUM BESYLATE			
AP	ABBOTT	10MG/ML	N74633 001 DEC 23, 1996	
AP	BEDFORD	10MG/ML	N74901 001 JUL 18, 1997	
AP	FAULDING	10MG/ML	N74740 001 MAR 28, 1997	> ADD > > ADD >
AP	GENSIA	10MG/ML	N74784 001 JUN 11, 1997	> ADD > > ADD >
AP	OHMEDA	10MG/ML	N74753 001 JAN 23, 1997	> ADD > > ADD > > DLT >
	ATRACURIUM BESYLATE PRESERVATIVE FREE			
AP	ABBOTT	10MG/ML	N74633 001 DEC 23, 1996	> DLT > > DLT >
AP		10MG/ML	N74639 001 MAR 25, 1997	> DLT > > DLT >
AP	BEDFORD	10MG/ML	N74900 001 JUL 18, 1997	> DLT >
AP	FAULDING	10MG/ML	N74741 001 MAR 28, 1997	
AP	OHMEDA	10MG/ML	N74768 001 JAN 23, 1997	

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

	TRACRIUM			
AP	+ GLAXO WELLCOME	10MG/ML	N18831 001 NOV 23, 1983	
AP	+	10MG/ML	N18831 002 JUN 20, 1985	
	TRACRIUM PRESERVATIVE FREE			
AP	+ GLAXO WELLCOME	10MG/ML	N18831 001 NOV 23, 1983	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	DIPHENOXYLATE HCL AND ATROPINE SULFATE		
AA	ROXANE	0.025MG;2.5MG	N86057 001
	@	0.025MG;2.5MG	N86057 001
	DIPHENOXYLATE HCL W/ ATROPINE SULFATE		
AA	ICN	0.025MG;2.5MG	N87195 001 FEB 16, 1982
	@	0.025MG;2.5MG	N87195 001 FEB 16, 1982
AA	KV PHARM	0.025MG;2.5MG	N85659 001
	@	0.025MG;2.5MG	N85659 001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ATROPINE AND DEMEROL		
+	ABBOTT	0.4MG/ML;50MG/ML	N87853 001 NOV 26, 1982
+		0.4MG/ML;75MG/ML	N87847 001 NOV 26, 1982
+		0.4MG/ML;100MG/ML	N87848 001 NOV 26, 1982
+	STERLING WINTHROP	0.4MG/ML;50MG/ML	N87853 001 NOV 26, 1982
+		0.4MG/ML;75MG/ML	N87847 001 NOV 26, 1982
+		0.4MG/ML;100MG/ML	N87848 001 NOV 26, 1982

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION
ZITHROMAX
+ PFIZER — EQ 500MG BASE/VIAL — N50733 001 JAN 30, 1997

BACITRACIN

INJECTABLE; INJECTION
BACIIM
AP PHARMA TEK — 50,000 UNITS/VIAL — N64153 001 MAY 09, 1997

BACITRACIN
AP + PHARMACIA AND UPJOHN — 50,000 UNITS/VIAL — N60733 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
CORTISPORIN
+ GLAXO WELLCOME — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM — N50168 002 MAY 04, 1984
+ MONARCH PHARMS — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM — N50168 002 MAY 04, 1984

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ
BN GLAXO WELLCOME — EQ 0.042MG DIPROP/SPRAY — N19389 001 JUL 27, 1987
BN + — EQ 0.042MG DIPROP/SPRAY — N19389 001 JUL 27, 1987

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL
EMETE-CON
+ ROERIG — EQ 100MG BASE — N16818 006
@ — EQ 100MG BASE — N16818 006

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE
@ ALPHARMA — EQ 0.05% BASE — N71085 001 FEB 03, 1987
AB NMC — EQ 0.05% BASE — N71085 001 FEB 03, 1987

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB FOUGERA — EQ 0.1% BASE — N18861 001 AUG 31, 1983
AB + — EQ 0.1% BASE — N18861 001 AUG 31, 1983

VALISONE
AB + SCHERING — EQ 0.1% BASE — N16322 001
EQ 0.01% BASE — N16322 002
@ — EQ 0.01% BASE — N16322 002
@ — EQ 0.1% BASE — N16322 001

LOTION; TOPICAL
BETAMETHASONE VALERATE
AB FOUGERA — EQ 0.1% BASE — N18866 001 AUG 31, 1983
AB + — EQ 0.1% BASE — N18866 001 AUG 31, 1983

VALISONE
AB + SCHERING — EQ 0.1% BASE — N16932 001
@ — EQ 0.1% BASE — N16932 001

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
AB FOUGERA — EQ 0.1% BASE — N18865 001 AUG 31, 1983
AB + — EQ 0.1% BASE — N18865 001 AUG 31, 1983

VALISONE
AB + SCHERING — EQ 0.1% BASE — N16740 001
@ — EQ 0.1% BASE — N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETOPTIC PILO
+ ALCON EQ 0.25% BASE;1.75% N20619 001 APR 17, 1997

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLENOXANE
AP + BRISTOL MYERS SQUIBB **EQ 30 UNITS BASE/VIAL** **N50443 002** SEP 07, 1995

BLEOMYCIN SULFATE
AP PHARMACIA AND UPJOHN **EQ 30 UNITS BASE/VIAL** **N64084 002** JUN 01, 1996
+ EQ 30 UNITS BASE/VIAL N64084 002 JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP + BAXTER HLTHCARE **200MG/100ML** **N19837 002** APR 12, 1989
AP + **400MG/100ML** **N19837 001** APR 12, 1989
@ 200MG/100ML N19837 002 APR 12, 1989
@ 400MG/100ML N19837 001 APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN
+ ALLERGAN 0.5% N20490 001 MAR 13, 1997

BROMFENAC SODIUM

CAPSULE; ORAL
DURACT
+ WYETH AYERST EQ 25MG BASE N20535 001 JUL 15, 1997

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT
+ ASTRA 0.05MG/INH N20233 001 FEB 14, 1994
+ 0.032MG/INH N20233 001 FEB 14, 1994

POWDER, METERED; INHALATION
PULMICORT
+ ASTRA 0.16MG/INH N20441 002 JUN 24, 1997
@ 0.32MG/INH N20441 003 JUN 24, 1997

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE
> ADD > AP ABBOTT **0.25MG/ML** **N74332 001** OCT 31, 1994
> ADD >
> DLT > AP SANOFI WINTHROP **0.25MG/ML** **N74332 001** OCT 31, 1994
> DLT >

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENORPHINE HCL
> ADD > AP ABBOTT **EQ 0.3MG BASE/ML** **N74137 001** JUN 03, 1996
> ADD >
> DLT > AP SANOFI WINTHROP **EQ 0.3MG BASE/ML** **N74137 001** JUN 03, 1996
> DLT >

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN
+ GLAXO WELLCOME 100MG N20358 002 OCT 04, 1996
+ 150MG N20358 003 OCT 04, 1996

ZYBAN
GLAXO WELLCOME 100MG N20711 002 MAY 14, 1997

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYBAN
GLAXO WELLCOME 150MG N20711 003 MAY 14, 1997
\+ 100MG N20711 002 MAY 14, 1997
\+ 150MG N20711 003 MAY 14, 1997

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT ONE
\+ SYNTEX 2% N19881 001 FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE PRESERVATIVE FREE
AP ABBOTT 1MG/ML N74620 001 JAN 22, 1997
AP 1MG/ML N74626 001 JAN 23, 1997
AP 2MG/ML N74620 002 JAN 22, 1997
AP 2MG/ML N74626 002 JAN 23, 1997
STADOL
AP \+ APOTHECON 2MG/ML N17857 004
STADOL PRESERVATIVE FREE
AP \+ APOTHECON 1MG/ML N17857 001
AP \+ 2MG/ML N17857 002

CALCIPOTRIENE

SOLUTION; TOPICAL
DOVONEX
\+ BRISTOL MYERS SQUIBB 0.005% N20611 001 MAR 03, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER
MCGAW 4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML N19634 002 FEB 24, 1988
@ 4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML N19634 002 FEB 24, 1988
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
AP MCGAW 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001
@ 20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML N17510 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
AP MCGAW 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18023 001
@ 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18023 001

CAPTOPRIL

TABLET; ORAL
CAPOTEN
AB * BRISTOL MYERS SQUIBB 25MG N18343 002
AB 25MG N18343 002
CAPTOPRIL
AB EGIS PHARMS 12.5MG N74748 004 MAY 29, 1997
AB 25MG N74748 002 MAY 29, 1997
AB 50MG N74748 001 MAY 29, 1997
AB 100MG N74748 003 MAY 29, 1997
AB PUREPAC PHARM 12.5MG N74640 001 MAR 31, 1997
AB 25MG N74640 002 MAR 31, 1997

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	PUREPAC PHARM	50MG	N74640 003 MAR 31, 1997	
AB		100MG	N74640 004 MAR 31, 1997	
AB	STASON	12.5MG	N74677 004 MAY 30, 1997	
AB		25MG	N74677 002 MAY 30, 1997	
AB		50MG	N74677 001 MAY 30, 1997	
AB		100MG	N74677 003 MAY 30, 1997	
AB	WOCKHARDT	12.5MG	N74532 001 MAR 28, 1997	
AB		25MG	N74532 002 MAR 28, 1997	
AB		50MG	N74532 003 MAR 28, 1997	
AB		100MG	N74532 004 MAR 28, 1997	

CARBAMAZEPINE

TABLET; ORAL
EPITOL

AB	LEMMON	200MG	N70541 001 SEP 17, 1986	
AB	TEVA	200MG	N70541 001 SEP 17, 1986	

TABLET, CHEWABLE; ORAL
EPITOL

AB	LEMMON	100MG	N73524 001 JUL 29, 1992	> ADD > > ADD > > ADD >
AB	TEVA	100MG	N73524 001 JUL 29, 1992	> ADD >

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB	LEMMON	10MG;100MG	N73618 001 AUG 28, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB	LEMMON	25MG;100MG	N73589 001 AUG 28, 1992
AB		25MG;250MG	N73607 001 AUG 28, 1992
AB	TEVA	10MG;100MG	N73618 001 AUG 28, 1992
AB		25MG;100MG	N73589 001 AUG 28, 1992
AB		25MG;250MG	N73607 001 AUG 28, 1992

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	AMIDE PHARM	350MG	N40188 001 MAR 07, 1997

CARVEDILOL

TABLET; ORAL
COREG

	SMITHKLINE BEECHAM	3.125MG	N20297 004 MAY 29, 1997

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB	RANBAXY	EQ 250MG BASE	N64156 001 AUG 28, 1997
AB		EQ 500MG BASE	N64156 002 AUG 28, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	LEMMON	EQ 250MG BASE/VIAL	N63016 001 MAR 14, 1989

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	LEMMON	EQ 500MG BASE/VIAL	N63016 002 MAR 14, 1989
AP		EQ 1GM BASE/VIAL	N63016 003 MAR 14, 1989
AP		EQ 5GM BASE/VIAL	N63018 001 MAR 05, 1990
AP		EQ 10GM BASE/VIAL	N63018 002 MAR 05, 1990
AP	TEVA	EQ 250MG BASE/VIAL	N63016 001 MAR 14, 1989
AP		EQ 500MG BASE/VIAL	N63016 002 MAR 14, 1989
AP		EQ 1GM BASE/VIAL	N63016 003 MAR 14, 1989
AP		EQ 5GM BASE/VIAL	N63018 001 MAR 05, 1990
AP		EQ 10GM BASE/VIAL	N63018 002 MAR 05, 1990

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL
CEFTIN

+	GLAXO WELLCOME	EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994
		EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994
+		EQ 250MG BASE/5ML	N50672 002 APR 29, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001 MAY 30, 1997
AP		EQ 1.5GM BASE/VIAL	N64125 002 MAY 30, 1997
AP		EQ 7.5GM BASE/VIAL	N64124 001 MAY 30, 1997

KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62591 001 JAN 10, 1986

CEFUROXIME SODIUM

INJECTABLE; INJECTION
KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62592 001 JAN 10, 1986
AP		EQ 750MG BASE/VIAL	N62591 001 JAN 10, 1986
AP		EQ 750MG BASE/VIAL	N62592 001 JAN 10, 1986

ZINACEF

AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002 OCT 19, 1983
AP	+	EQ 750MG BASE/VIAL	N50558 002 OCT 19, 1983

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	APOTHECON	EQ 250MG BASE	N62973 001 NOV 08, 1988
AB		EQ 500MG BASE	N62974 001 NOV 23, 1988
	@	EQ 250MG BASE	N62973 001 NOV 08, 1988
	@	EQ 500MG BASE	N62974 001 NOV 23, 1988
AB	PUREPAC PHARM	EQ 250MG BASE	N62809 001 APR 22, 1987
AB		EQ 500MG BASE	N62809 002 APR 22, 1987
	@	EQ 250MG BASE	N62809 001 APR 22, 1987
	@	EQ 500MG BASE	N62809 002 APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

	APOTHECON	EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
		EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
	@	EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

@	APOTHECON	EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

@	BAYER	0.05MG	N20740 001 JUN 26, 1997
@		0.1MG	N20740 002 JUN 26, 1997
		0.2MG	N20740 003 JUN 26, 1997
+		0.3MG	N20740 004 JUN 26, 1997

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

+	PARKE DAVIS	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002
@		10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE

	PARKE DAVIS	EQ 150MG BASE/5ML	N62301 001
@		EQ 150MG BASE/5ML	N62301 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

	ROCHE	10MG	N85481 001
@		10MG	N85481 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	LEMMON	0.12%	N74522 001 DEC 15, 1995
AT	TEVA	0.12%	N74522 001 DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE-MPF

AP	+	ASTRA	2%	N09435 003
AP	+		2%	N09435 006 MAY 02, 1996
AP	+		3%	N09435 004
AP	+		3%	N09435 007 MAY 02, 1996
	@		2%	N09435 003
	@		3%	N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA		KV PHARM	4MG	N87164 001
	@		4MG	N87164 001
		KLOROMIN		
AA		HALSEY	4MG	N83629 001
	@		4MG	N83629 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

	@	LEMMON	50MG	N88651 001 MAY 30, 1985
> DLT >	AB	PUREPAC PHARM	25MG	N88139 001 JUL 16, 1986
> DLT >	AB		50MG	N88140 001 AUG 11, 1983
> ADD >		@	25MG	N88139 001 JUL 16, 1986
> ADD >		@	50MG	N88140 001 AUG 11, 1983

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
	@ TEVA	50MG	N88651 001	MAY 30, 1985
	THALITONE			
BX	HORUS THERAP	25MG	N88051 001	NOV 12, 1982
	+	15MG	N19574 001	DEC 20, 1988
BX	MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992
	+	15MG	N19574 001	DEC 20, 1988
	@	25MG	N88051 001	NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	LEMMON	500MG	N89859 001	MAY 04, 1988
AA	TEVA	500MG	N89859 001	MAY 04, 1988
	PARAFLEX			
> DLT > AA	+ JOHNSON RW	250MG	N11300 003	
> ADD >	@	250MG	N11300 003	

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997

CICLOPIROX

GEL; TOPICAL

	LOPROX			
	+ HOECHST MARION RSSL	0.77%	N20519 001	JUL 21, 1997

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	LEMMON	200MG	N74365 001	FEB 28, 1995
AB		300MG	N74365 002	FEB 28, 1995
AB		400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995
AB	SIDMAK LABS NJ	200MG	N74568 001	FEB 27, 1997
AB		300MG	N74568 002	FEB 27, 1997
AB		400MG	N74568 003	FEB 27, 1997
AB		800MG	N74566 001	FEB 27, 1997
AB	TEVA	200MG	N74365 001	FEB 28, 1995
AB		300MG	N74365 002	FEB 28, 1995
AB		400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995

CIMETIDINE HYDROCHLOROIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL			
> ADD > AP	ABBOTT	EQ 300MG BASE/2ML	N74296 001	MAR 28, 1997
> ADD > AP		EQ 300MG BASE/2ML	N74412 001	MAR 28, 1997
> DLT > AP	SANOFI	EQ 300MG BASE/2ML	N74296 001	MAR 28, 1997
> DLT > AP		EQ 300MG BASE/2ML	N74412 001	MAR 28, 1997

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001	JAN 27, 1997
> ADD > AA	ROXANE	EQ 300MG BASE/5ML	N74541 001	AUG 05, 1997

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994
AA	TEVA	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994

TABLET; ORAL
CLEMASTINE FUMARATE

AB	LEMMON	2.68MG	N73283 001 JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992
AB	TEVA	2.68MG	N73283 001 JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	QUAD PHARMS	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987
	@	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	FOUGERA	EQ 1% BASE	N64159 001 JUN 05, 1997
AT	LEMMON	EQ 1% BASE	N62930 001 JUN 28, 1989
AT	MORTON GROVE	EQ 1% BASE	N63304 001 JUL 15, 1997
AT	TEVA	EQ 1% BASE	N62930 001 JUN 28, 1989

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CORMAX

AB	HEALTHPOINT	0.05%	N74220 001 MAY 16, 1997

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	INVAMED	25MG	N74953 001 JUN 25, 1997
AB		50MG	N74953 002 JUN 25, 1997
AB		75MG	N74953 003 JUN 25, 1997
AB	LEMMON	25MG	N74958 001 AUG 26, 1997
AB		50MG	N74958 002 AUG 26, 1997
AB		75MG	N74958 003 AUG 26, 1997
AB	NOVOPHARM	25MG	N74849 001 APR 04, 1997
AB		50MG	N74849 002 APR 04, 1997
AB		75MG	N74849 003 APR 04, 1997

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB	EON	0.5MG	N74979 001 AUG 29, 1997
AB		1MG	N74979 002 AUG 29, 1997
AB		2MG	N74979 003 AUG 29, 1997
+	KLONOPIN ROCHE	0.125MG	N17533 005 APR 09, 1997
		0.25MG	N17533 006 APR 09, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB	PUREPAC PHARM	7.5MG	N71925 001 APR 25, 1988
AB		15MG	N71926 001 APR 25, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

	@	PUREPAC PHARM	7.5MG	N71925 001 APR 25, 1988
	@		15MG	N71926 001 APR 25, 1988

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

> DLT >	AB	PUREPAC PHARM	3.75MG	N72330 001 AUG 08, 1988
> DLT >	AB		7.5MG	N72331 001 AUG 08, 1988
> DLT >	AB		15MG	N72332 001 AUG 08, 1988
> ADD >	@		3.75MG	N72330 001 AUG 08, 1988
> ADD >	@		7.5MG	N72331 001 AUG 08, 1988
> ADD >	@		15MG	N72332 001 AUG 08, 1988

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE W/ CODEINE

	AA	HALSEY	10MG/5ML;6.25MG/5ML	N88739 001 DEC 23, 1988
	@		10MG/5ML;6.25MG/5ML	N88739 001 DEC 23, 1988

PROMETHAZINE HCL AND CODEINE PHOSPHATE

> ADD >	AA	HI TECH PHARMA	10MG/5ML;6.25MG/5ML	N40151 001 AUG 26, 1997

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL

	+	FISONS	0.8MG/INH	N18887 001 DEC 05, 1985
	+	RHONE POULENC RORER	0.8MG/INH	N18887 001 DEC 05, 1985

CAPSULE; INHALATION
INTAL

	+	FISONS	20MG	N16990 001

CROMOLYN SODIUM

CAPSULE; INHALATION
INTAL

	+	RHONE POULENC RORER	20MG	N16990 001

SOLUTION; INHALATION
INTAL

AN	+	FISONS	10MG/ML	N18596 001 MAY 28, 1982
AN	+	RHONE POULENC RORER	10MG/ML	N18596 001 MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC
OPTICROM

	@	FISONS	4%	N18155 001 OCT 03, 1984
	@	RHONE POULENC RORER	4%	N18155 001 OCT 03, 1984

SPRAY, METERED; NASAL
NASALCROM

	+	FISONS	5.2MG/SPRAY	N18306 001 MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION
COBAVITE

AP		STERIS	0.1MG/ML	N83013 001
AP			1MG/ML	N83064 001
	@		0.1MG/ML	N83013 001
	@		1MG/ML	N83064 001

CYANOCOBALAMIN

AP		STERIS	0.1MG/ML	N83120 001
	@		0.1MG/ML	N83120 001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A
DICOPAC KIT

	AMERSHAM	N/A;N/A;N/A	N17406 001
	MEDI PHYSICS	N/A;N/A;N/A	N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AK-PENTOLATE			
AT	AKORN	**1%**		**N85555 001**
	@	1%		N85555 001
	AKPENTOLATE			
AT	AKORN	**1%**		**N40164 001**
				JAN 13, 1997
AT		**2%**		**N40165 001**
				JAN 13, 1997
	CYCLOGYL			
AT	+ ALCON	**2%**		**N84108 001**

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	ASTA	**100MG/VIAL**		**N88371 001**
				JUL 03, 1986
AP		**200MG/VIAL**		**N88372 001**
				JUL 03, 1986
AP		**500MG/VIAL**		**N88373 001**
				JUL 03, 1986
AP		**1GM/VIAL**		**N88374 001**
				SEP 24, 1986
AP	ELKINS SINN	**100MG/VIAL**		**N88371 001**
				JUL 03, 1986
AP		**200MG/VIAL**		**N88372 001**
				JUL 03, 1986
AP		**500MG/VIAL**		**N88373 001**
				JUL 03, 1986
AP		**1GM/VIAL**		**N88374 001**
				SEP 24, 1986
	CYTOXAN			
AP	+ BRISTOL MYERS SQUIBB	**100MG/VIAL**		**N12142 001**
AP	+	**200MG/VIAL**		**N12142 002**
AP	+	**500MG/VIAL**		**N12142 003**
AP	+	**1GM/VIAL**		**N12142 004**
				AUG 30, 1982
AP	+	**2GM/VIAL**		**N12142 005**
				AUG 30, 1982
	@	100MG/VIAL		N12142 001
	@	200MG/VIAL		N12142 002
	@	500MG/VIAL		N12142 003
	@	1GM/VIAL		N12142 004
				AUG 30, 1982

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYTOXAN			
	@ BRISTOL MYERS SQUIBB	2GM/VIAL		N12142 005
				AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	HALSEY	**4MG**		**N89057 001**
				JUL 03, 1986
	@	4MG		N89057 001
				JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	CERUBIDINE			
AP	RHONE POULENC RORER	**EQ 20MG BASE/VIAL**		**N61876 001**
	@	EQ 20MG BASE/VIAL		N61876 001
AP	+ WYETH AYERST	**EQ 20MG BASE/VIAL**		**N50484 001**
	@	EQ 20MG BASE/VIAL		N50484 001
	DAUNORUBICIN HCL			
AP	BEDFORD	**EQ 20MG BASE/VIAL**		**N64103 001**
				FEB 03, 1995
	+	EQ 20MG BASE/VIAL		N64103 001
				FEB 03, 1995

DELAVIRDINE MESYLATE

TABLET; ORAL

	RESCRIPTOR			
	+ PHARMACIA AND UPJOHN	100MG		N20705 001
				APR 04, 1997

DESERPIDINE

TABLET; ORAL

	HARMONYL			
	+ ABBOTT	0.25MG		N10796 002
	@	0.25MG		N10796 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL

AB	SIDMAK LABS NJ	100MG	N71803 001	MAY 29, 1997
AB		150MG	N71804 001	MAY 29, 1997

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

> DLT >	+	RHONE POULENC RORER	0.01MG/SPRAY	N17922 002
> DLT >				FEB 06, 1989
> ADD >	@		0.01MG/SPRAY	N17922 002
> ADD >				FEB 06, 1989
> ADD >	+		0.01MG/SPRAY	N17922 003
> ADD >				AUG 07, 1996

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA	ALPHARMA	0.5MG/5ML	N88997 001	OCT 10, 1986
	@	0.5MG/5ML	N88997 001	OCT 10, 1986

GEL; TOPICAL
DECADERM

+	MERCK SHARP DOHME	0.1%	N13538 001
@		0.1%	N13538 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXASPORIN

AT	BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64063 001	JUL 25, 1994

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64063 001	JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL
DECADRON

+	MERCK SHARP DOHME	EQ 0.1% PHOSPHATE	N11983 002
@		EQ 0.1% PHOSPHATE	N11983 002

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001
@		EQ 4MG PHOSPHATE/ML	N84355 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;37MG/100ML	N19699 001 SEP 29, 1989
@		5GM/100ML;37MG/100ML	N19699 001 SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML;75MG/100ML	N19699 002 SEP 29, 1989
@		5GM/100ML;75MG/100ML	N19699 002 SEP 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;110MG/100ML	N19699 003 SEP 29, 1989
@		5GM/100ML;110MG/100ML	N19699 003 SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;220MG/100ML	N19699 005 SEP 29, 1989
@		5GM/100ML;220MG/100ML	N19699 005 SEP 29, 1989

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	10GM/100ML;900MG/100ML	N18047 001
@		10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML;900MG/100ML	N18026 001

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
@ MCGAW 5GM/100ML;900MG/100ML N18026 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL
CHOLOXIN
KNOLL PHARM 1MG N12302 005
2MG N12302 002
+ 4MG N12302 004
@ 1MG N12302 005
@ 2MG N12302 002
@ 4MG N12302 004

DIAZEPAM

GEL; RECTAL
DIASTAT
+ ATHENA 2.5MG/0.5ML N20648 001 JUL 29, 1997
5MG/ML N20648 002 JUL 29, 1997
10MG/2ML N20648 003 JUL 29, 1997
15MG/3ML N20648 004 JUL 29, 1997
+ 20MG/4ML N20648 005 JUL 29, 1997

INJECTABLE; INJECTION
DIAZEPAM
> ADD > **AP** ABBOTT **5MG/ML** **N72079 001** DEC 20, 1988 > DLT >
> ADD > **AP** STERIS **5MG/ML** **N70912 001** AUG 28, 1986 > DLT >
@ 5MG/ML N70912 001 AUG 28, 1986 > ADD >
> DLT > **AP** STERLING WINTHROP **5MG/ML** **N72079 001** DEC 20, 1988 > DLT >
> DLT > > ADD >

TABLET; ORAL
DIAZEPAM
AB HALSEY **2MG** **N70987 001** AUG 15, 1986

DIAZEPAM

TABLET; ORAL
DIAZEPAM
AB HALSEY **5MG** **N70996 001** AUG 15, 1986
AB **10MG** **N70956 001** AUG 15, 1986
@ 2MG N70987 001 AUG 15, 1986
@ 5MG N70996 001 AUG 15, 1986
@ 10MG N70956 001 AUG 15, 1986

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM
AB COPLEY PHARM **25MG** **N74459 001** JUN 25, 1997
AB **50MG** **N74459 002** JUN 25, 1997
AB **75MG** **N74459 003** JUN 25, 1997

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL
AB WEST WARD **10MG** **N40204 001** FEB 28, 1997

SYRUP; ORAL
BENTYL
AA + HOECHST MARION RSSL **10MG/5ML** **N07961 002** OCT 15, 1984
+ 10MG/5ML N07961 002 OCT 15, 1984
DICYCLOMINE HCL
AA ALPHARMA **10MG/5ML** **N84479 001**
@ 10MG/5ML N84479 001

DIETHYLSTILBESTROL

TABLET; ORAL

DIETHYLSTILBESTROL				
LILLY	1MG	N04041 004	> ADD >	
+	5MG	N04041 005	> ADD	
@	1MG	N04041 004		
@	5MG	N04041 005		
STILBESTROL				
TABLICAPS	0.5MG	N83004 001		
@	0.5MG	N83004 001		

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL			
AB DANBURY PHARMA	250MG	N74400 001	JUL 17, 1997
AB	500MG	N74400 002	JUL 17, 1997

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN				
> ADD > AP ABBOTT	0.25MG/ML	N40093 001		MAY 16, 1996
> DLT > AP SANOFI WINTHROP	0.25MG/ML	N40093 001		MAY 16, 1996
DIGOXIN PEDIATRIC				
> ADD > AP ABBOTT	0.1MG/ML	N40092 001		APR 25, 1996
> DLT > AP SANOFI WINTHROP	0.1MG/ML	N40092 001		APR 25, 1996

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL			
AB MYLAN	60MG	N74910 001	MAY 02, 1997
AB	90MG	N74910 002	MAY 02, 1997
AB	120MG	N74910 003	MAY 02, 1997

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HCL				
> ADD > AP GENSIA	5MG/ML	N74894 001		AUG 26, 1997

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE			
AP ELKINS SINN	50MG/ML	N84767 001	
@	50MG/ML	N84767 001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL			
> DLT > AA EON	25MG	N80845 002	
> DLT > AA	50MG	N80845 001	
> ADD > @	25MG	N80845 002	
> ADD > @	50MG	N80845 001	

INJECTABLE; INJECTION

BENADRYL			
> DLT > AP + PARKE DAVIS	10MG/ML	N06146 001	
> DLT > AP +	50MG/ML	N09486 001	
> ADD > @	10MG/ML	N06146 001	
BENADRYL PRESERVATIVE FREE			
> ADD > AP + PARKE DAVIS	50MG/ML	N09486 001	
DIPHENHYDRAMINE HCL			
> DLT > AP FUJISAWA	50MG/ML	N80586 002	
> DLT > AP INTL MEDICATION	50MG/ML	N84094 001	
> DLT > AP STERIS	10MG/ML	N80873 001	
AP	10MG/ML	N83533 001	
> ADD > +	10MG/ML	N80873 001	
@	10MG/ML	N83533 001	
DIPHENHYDRAMINE HCL PRESERVATIVE FREE			
> ADD > AP FUJISAWA	50MG/ML	N80586 002	
> ADD > AP INTL MEDICATION	50MG/ML	N84094 001	
> ADD > AP STERIS	50MG/ML	N80873 003	

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	CHELSEA LABS	50MG	N87160 001 JUN 07, 1996	

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

+	LILLY	250MG	N50678 001 JUN 19, 1995	> ADD > > ADD >
@		250MG	N50678 001 JUN 19, 1995	> DLT > > DLT >

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

> ADD > > ADD >	AP	ABBOTT	EQ 12.5MG BASE/ML	N74292 001 FEB 16, 1995	
> DLT > > DLT >	AP	SANOFI WINTHROP	EQ 12.5MG BASE/ML	N74292 001 FEB 16, 1995	

DOXAZOSIN MESYLATE

TABLET; ORAL
CARDURA

	PFIZER	EQ 1MG BASE	N19668 001 NOV 02, 1990	
+		EQ 8MG BASE	N19668 004 NOV 02, 1990	
+		EQ 1MG BASE	N19668 001 NOV 02, 1990	
		EQ 8MG BASE	N19668 004 NOV 02, 1990	

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL
DORYX

AB	PARKE DAVIS	EQ 100MG BASE	N62653 001 OCT 30, 1985	

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL
DORYX

AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001 OCT 30, 1985	

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

> ADD > > ADD >	AP	ABBOTT	2.5MG/ML	N72272 001 AUG 31, 1995
> DLT > > DLT >	AP	SANOFI WINTHROP	2.5MG/ML	N72272 001 AUG 31, 1995

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

+	J AND J	1%	N18751 001 DEC 23, 1982	
+	JOHNSON RW	1%	N18751 001 DEC 23, 1982	

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	STIEFEL	2%	N64127 001 FEB 14, 1997	

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

> ADD > > ADD >	AB	ROYCE LABS	1MG	N74818 001 AUG 19, 1997
> ADD > > ADD >	AB		2MG	N74818 002 AUG 19, 1997
	AB	TEVA	1MG	N74921 001 JUL 10, 1997
	AB		2MG	N74921 002 JUL 10, 1997

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB	ZENITH GOLDLINE	1MG	N74826 001	JUL 03, 1997
AB		2MG	N74826 002	JUL 03, 1997

PROSOM

AB	ABBOTT	1MG	N19080 001	DEC 26, 1990
AB +		2MG	N19080 002	DEC 26, 1990

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

+	WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997

TABLET; ORAL-28

ALESSE

	WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB	ENDO LABS	200MG	N74842 001	JUL 17, 1997
AB		300MG	N74842 002	JUL 17, 1997
>ADD> AB	GENEVA PHARMS	200MG	N74840 001	AUG 29, 1997
>ADD> AB		300MG	N74840 002	AUG 29, 1997
AB	MYLAN	200MG	N74932 001	MAY 16, 1997
AB		300MG	N74932 002	MAY 16, 1997
AB	ZENITH GOLDLINE	200MG	N74899 001	JUL 08, 1997
AB		300MG	N74899 002	JUL 08, 1997

ETODOLAC

CAPSULE; ORAL

LODINE

AB	WYETH AYERST	200MG	N18922 002	JAN 31, 1991
AB +		300MG	N18922 003	JAN 31, 1991

TABLET; ORAL

ETODOLAC

AB	ENDO LABS	400MG	N74841 001	JUN 27, 1997
AB	EON	400MG	N74903 001	APR 11, 1997
AB	GENEVA PHARMS	400MG	N74839 001	JUL 11, 1997
AB	INVAMED	400MG	N74846 001	FEB 28, 1997
AB	PUREPAC PHARM	400MG	N74819 001	FEB 28, 1997
AB	ROYCE LABS	400MG	N74892 001	APR 16, 1997
AB	ZENITH GOLDLINE	400MG	N74883 001	FEB 28, 1997

LODINE

AB	WYETH AYERST	400MG	N18922 004	JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP	IMMUNEX	20MG/ML	N74513 001	MAR 14, 1996
AP	PIERRE FABRE	20MG/ML	N74813 001	JUL 09, 1997
AP	SUPERGEN	20MG/ML	N74513 001	MAR 14, 1996

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

>ADD> AP	ABBOTT	EQ 0.05MG BASE/ML	N72786 001	SEP 24, 1991

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

> DLT >	**AP**	STERLING WINTHROP	**EQ 0.05MG BASE/ML**	**N72786 001**	**SEP 24, 1991**
> DLT					

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

@ 3M		50MG	N18830 004	AUG 23, 1988
@		100MG	N18830 001	OCT 31, 1985
@		150MG	N18830 003	JUN 03, 1988
		50MG	N18830 004	AUG 23, 1988
		100MG	N18830 001	OCT 31, 1985
+		150MG	N18830 003	JUN 03, 1988

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN

+ PFIZER		200MG/100ML	N19950 001	JAN 29, 1990

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PFIZER		200MG/100ML	N19950 003	SEP 29, 1992
@		2MG/ML	N19950 005	JUL 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ PFIZER		200MG/100ML	N19950 001	JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ PFIZER		200MG/100ML	N19950 002	JAN 29, 1990
@		2MG/ML	N19950 004	JUL 08, 1994

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE

BX	+	DURA	0.025MG/SPRAY	N18148 001	
BX	**+**	**SYNTEX**	**0.025MG/SPRAY**	**N18148 001**	

NASAREL

BX	+	DURA	0.025MG/SPRAY	N20409 001	MAR 08, 1995
BX	**+**	**SYNTEX**	**0.025MG/SPRAY**	**N20409 001**	**MAR 08, 1995**

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCET

	@	ALPHARMA	0.025%	N88360 001	JAN 16, 1984
AT		**NMC**	**0.025%**	**N88360 001**	**JAN 16, 1984**

FLUOCINOLONE ACETONIDE

	@	ALPHARMA	0.01%	N88361 001	JAN 16, 1984
AT		**NMC**	**0.01%**	**N88361 001**	**JAN 16, 1984**

SYNALAR

AT	+	MEDICIS	**0.01%**	**N12787 004**
AT	+		**0.025%**	**N12787 002**
AT	+		**0.025%**	**N12787 005**
AT	+	**SYNTEX**	**0.01%**	**N12787 004**
AT	+		**0.025%**	**N12787 002**
AT	+		**0.025%**	**N12787 005**

SYNALAR-HP

	+	MEDICIS	0.2%	N16161 002
	+	SYNTEX	0.2%	N16161 002

OINTMENT; TOPICAL
SYNALAR

AT	+	MEDICIS	**0.025%**	**N13960 001**
AT	+	SYNTEX	**0.025%**	**N13960 001**

SOLUTION; TOPICAL
SYNALAR

AT	+	MEDICIS	**0.01%**	**N15296 001**
AT	+	SYNTEX	**0.01%**	**N15296 001**

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR
+ MEDICIS 0.025%;EQ 3.5MG BASE/GM N60700 001
+ SYNTEX 0.025%;EQ 3.5MG BASE/GM N60700 001

FLUOCINONIDE

CREAM; TOPICAL
LIDEX
AB + MEDICIS 0.05% N16908 002
AB + SYNTEX 0.05% N16908 002
LIDEX-E
AB MEDICIS 0.05% N16908 003
AB SYNTEX 0.05% N16908 003

GEL; TOPICAL
FLUOCINONIDE
AB TARO 0.05% N74935 001
JUL 29, 1997
LIDEX
AB + MEDICIS 0.05% N17373 001
AB + SYNTEX 0.05% N17373 001

OINTMENT; TOPICAL
FLUOCINONIDE
>ADD< AB ALTANA 0.05% N74905 001
>ADD< AUG 26, 1997
LIDEX
AB + MEDICIS 0.05% N16909 002
AB + SYNTEX 0.05% N16909 002

SOLUTION; TOPICAL
LIDEX
AT + MEDICIS 0.05% N18849 001
APR 06, 1984
AT + SYNTEX 0.05% N18849 001
APR 06, 1984

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP
+ LILLY 0.025% N12806 003
+ 0.05% N12806 002
+ OCLASSEN 0.025% N12806 003

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP
+ OCLASSEN 0.05% N12806 002

LOTION; TOPICAL
CORDRAN
AT + LILLY 0.05% N13790 001
AT + OCLASSEN 0.05% N13790 001

OINTMENT; TOPICAL
CORDRAN
+ LILLY 0.025% N12806 004
+ 0.05% N12806 001
+ OCLASSEN 0.025% N12806 004
+ 0.05% N12806 001

TAPE; TOPICAL
CORDRAN
+ LILLY 0.004MG/SQ CM N16455 001
+ OCLASSEN 0.004MG/SQ CM N16455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL
AB HALSEY 15MG N71808 001
JAN 07, 1988
AB 30MG N71809 001
JAN 07, 1988
@ 15MG N71808 001
JAN 07, 1988
@ 30MG N71809 001
JAN 07, 1988

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
AB SIDMAK LABS NJ 50MG N74647 001
APR 01, 1997
AB 100MG N74647 002
APR 01, 1997
AB WARNER CHILCOTT 100MG N74560 002
MAY 16, 1997

FOLIC ACID

TABLET; ORAL

		FOLIC ACID		
AA		DANBURY PHARMA	1MG	N80680 001
AA	+		1MG	N80680 001
		FOLVITE		
AA	+	LEDERLE	1MG	N05897 004
		@	1MG	N05897 004

FUROSEMIDE

INJECTABLE; INJECTION

		FUROSEMIDE		
> ADD >	AP	ABBOTT	10MG/ML	N70578 001 JUL 08, 1987
> ADD >				
> ADD >	AP		10MG/ML	N72080 001 AUG 13, 1991
> ADD >				
> ADD >	AP		10MG/ML	N74337 001 OCT 31, 1994
> ADD >				
> DLT >	AP	SANOFI WINTHROP	10MG/ML	N74337 001 OCT 31, 1994
> DLT >				
> DLT >	AP	STERLING WINTHROP	10MG/ML	N70578 001 JUL 08, 1987
> DLT >				
> DLT >	AP		10MG/ML	N72080 001 AUG 13, 1991
> DLT >				

GENTAMICIN SULFATE

CREAM; TOPICAL

		GENTAMICIN SULFATE		
> ADD >		@ ALPHARMA	EQ 0.1% BASE	N62471 001 SEP 27, 1983
> ADD >				
> DLT >	AT	NMC	EQ 0.1% BASE	N62471 001 SEP 27, 1983
> DLT >				

OINTMENT; TOPICAL

		GENTAMICIN SULFATE		
> ADD >		@ ALPHARMA	EQ 0.1% BASE	N62496 001 MAR 14, 1984
> ADD >				
> DLT >	AT	NMC	EQ 0.1% BASE	N62496 001 MAR 14, 1984
> DLT >				

GLIPIZIDE

TABLET; ORAL

		GLIPIZIDE		
AB		SIDMAK LABS NJ	5MG	N74619 001 APR 04, 1997
AB			10MG	N74619 002 APR 04, 1997

GLUTETHIMIDE

TABLET; ORAL

		GLUTETHIMIDE		
AA		HALSEY	500MG	N89459 001 OCT 10, 1986
		@	500MG	N89459 001 OCT 10, 1986

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

		GRIFULVIN V		
	+	J AND J	125MG/5ML	N50448 001
			125MG/5ML	N62483 001 JAN 26, 1984
	+	JOHNSON RW	125MG/5ML	N50448 001
			125MG/5ML	N62483 001 JAN 26, 1984

TABLET; ORAL

		GRIFULVIN V		
AB		J AND J	250MG	N60618 002
AB			250MG	N62279 002
AB			500MG	N60618 003
AB			500MG	N62279 003
			125MG	N60618 001
			125MG	N62279 001
AB		JOHNSON RW	250MG	N60618 002
AB			250MG	N62279 002
AB			500MG	N60618 003
AB			500MG	N62279 003
			125MG	N60618 001
			125MG	N62279 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HCL

AB	AMIDE PHARM	EQ 1MG BASE	N74673 001 FEB 28, 1997		
AB		EQ 2MG BASE	N74673 002 FEB 28, 1997		
AB	MYLAN	EQ 1MG BASE	N74796 001 JAN 27, 1997		
AB		EQ 2MG BASE	N74796 002 JAN 27, 1997	> ADD >	
AB	ROYCE LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997	> ADD >	
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997	> ADD >	

HALCINONIDE

CREAM; TOPICAL

HALOG

	WESTWOOD SQUIBB	0.025%	N17818 001	> ADD >	
	@	0.025%	N17818 001	> DLT >	

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

+	JOHNSON RW	EQ 50MG BASE/ML	N18701 001 JAN 14, 1986	> DLT >	
+		EQ 100MG BASE/ML	N18701 002 JAN 31, 1997	> DLT >	

HALDOL DECANOATE 100

+	JOHNSON RW	EQ 100MG BASE/ML	N18701 002 OCT 31, 1989	> ADD >	

HALDOL DECANOATE 50

+	JOHNSON RW	EQ 50MG BASE/ML	N18701 001 JAN 14, 1986	> ADD >	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

AP	FUJISAWA	10 UNITS/ML	N17029 017 DEC 05, 1985	> DLT >	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

AP	FUJISAWA	100 UNITS/ML	N17029 018 DEC 05, 1985		
	@	10 UNITS/ML	N17029 017 DEC 05, 1985		
	@	100 UNITS/ML	N17029 018 DEC 05, 1985		

HEPARIN LOCK FLUSH

AP	ABBOTT	10 UNITS/ML	N40082 001 FEB 28, 1995		
AP		10 UNITS/ML	N88097 001 APR 28, 1983		
AP		10 UNITS/ML	N88346 001 MAY 18, 1983		
AP		100 UNITS/ML	N40082 002 FEB 28, 1995		
AP		100 UNITS/ML	N88098 001 APR 28, 1983		
AP		100 UNITS/ML	N88347 001 MAY 18, 1983		
AP	SANOFI WINTHROP	10 UNITS/ML	N40082 001 FEB 28, 1995		
AP		100 UNITS/ML	N40082 002 FEB 28, 1995		
AP	STERLING WINTHROP	10 UNITS/ML	N88097 001 APR 28, 1983		
AP		10 UNITS/ML	N88346 001 MAY 18, 1983		
AP		100 UNITS/ML	N88098 001 APR 28, 1983		
AP		100 UNITS/ML	N88347 001 MAY 18, 1983		

HEPARIN SODIUM

AP	ABBOTT	2,500 UNITS/ML	N88099 001 APR 28, 1983		
AP		5,000 UNITS/ML	N88100 001 APR 28, 1983		
AP		10,000 UNITS/ML	N40095 001 JUL 26, 1996		
AP	FUJISAWA	20,000 UNITS/ML	N17029 004		
AP	SANOFI WINTHROP	10,000 UNITS/ML	N40095 001 JUL 26, 1996		
AP	STERIS	1,000 UNITS/ML	N17064 002		
	@	1,000 UNITS/ML	N17064 002		
AP	STERLING WINTHROP	2,500 UNITS/ML	N88099 001 APR 28, 1983		

HEPARIN SODIUM

INJECTABLE; INJECTION

		HEPARIN SODIUM			
> DLT >	**AP**	STERLING WINTHROP	**5,000 UNITS/ML**	**N88100 001**	
> DLT				APR 28, 1983	
		HEPARIN SODIUM PRESERVATIVE FREE			
> ADD >	**AP** +	ABBOTT	**10,000 UNITS/ML**	**N89522 001**	
> ADD >				MAY 04, 1987	
> DLT >	**AP** +	STERLING WINTHROP	**10,000 UNITS/ML**	**N89522 001**	
> DLT >				MAY 04, 1987	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

	HYDROPANE			
AA	HALSEY	**1.5MG/5ML;5MG/5ML**	**N88066 001**	
			JUN 28, 1985	
	@	1.5MG/5ML;5MG/5ML	N88066 001	
			JUN 28, 1985	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL		
AP	LUITPOLD	**20MG/ML**	**N40136 001**
			JUN 30, 1997

TABLET; ORAL

	HYDRALAZINE HCL		
AA	HALSEY	**25MG**	**N89130 001**
			JAN 15, 1986
AA		**100MG**	**N89178 001**
			JAN 15, 1986
	@	25MG	N89130 001
			JAN 15, 1986
	@	100MG	N89178 001
			JAN 15, 1986
> DLT >	PUREPAC PHARM	25MG	N88177 001
> DLT >			JUL 29, 1983
> ADD >	@	25MG	N88177 001
> ADD >			JUL 29, 1983

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

		METHYLDOPA AND HYDROCHLOROTHIAZIDE		
> DLT >	**AB**	PUREPAC PHARM	**15MG;250MG**	**N70853 001**
> DLT >				OCT 08, 1986
> DLT >	**AB**		**25MG;250MG**	**N70688 001**
> DLT >				APR 24, 1986
> DLT >	**AB**		**30MG;500MG**	**N70854 001**
> DLT >				OCT 08, 1986
> ADD >		@	15MG;250MG	N70853 001
> ADD >				OCT 08, 1986
> ADD >		@	25MG;250MG	N70688 001
> ADD >				APR 24, 1986
> ADD >		@	30MG;500MG	N70854 001
> ADD >				OCT 08, 1986

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIRETIC		
	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001
			JUN 27, 1997
+		25MG;15MG	N20729 002
			JUN 27, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE		
AB	GENEVA PHARMS	**25MG;37.5MG**	**N74821 001**
			JUN 05, 1997

HYDROCORTISONE

CREAM; TOPICAL

	DERMACORT		
AT	MONARCH PHARMS	**1%**	**N83011 002**
AT	SOLVAY	**1%**	**N83011 002**
	HYDROCORTISONE		
	@ ALPHARMA	2.5%	N89754 001
			FEB 01, 1989
AT	NMC	**2.5%**	**N89754 001**
			FEB 01, 1989
	PROCTOCORT		
AT	MONARCH PHARMS	**1%**	**N83011 001**

HYDROCORTISONE

CREAM; TOPICAL

	PROCTOCORT			
AT	SOLVAY	1%		N83011 001
	SYNACORT			
AT	MEDICIS	1%		N87458 001
AT		2.5%		N87457 001
@		0.5%		N87459 001
AT	SYNTEX	1%		N87458 001
AT		2.5%		N87457 001
@		0.5%		N87459 001

TABLET; ORAL

	HYDROCORTISONE		
BP	PUREPAC PHARM	10MG	N84247 003 AUG 31, 1982
BP		20MG	N84247 002
@		10MG	N84247 003 AUG 31, 1982
@		20MG	N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

	CORTISPORIN			
AT	+ GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N50479 001
AT	+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N50479 001
	OTOCORT			
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N60730 002
@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N60730 002

SUSPENSION/DROPS; OTIC

	OTOCORT			
AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62521 001 JUL 11, 1985
@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62521 001 JUL 11, 1985
	PEDIOTIC			
AT	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62822 001 SEP 29, 1987

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

	PEDIOTIC			
AT	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62822 001 SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL

	ALPHADERM		
@	BIOGLAN	1%;10%	N86008 001
@	VIVAN	1%;10%	N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HEMSOL-HC			
AT	ABLE	1%		N81274 001 JUN 19, 1992
+		1%		N81274 001 JUN 19, 1992
	HYDROCORTISONE ACETATE			
AT	+ PUREPAC PHARM	1%		N86052 001
@		1%		N86052 001

INJECTABLE; INJECTION

	HYDROCORTISONE ACETATE		
BP	AKORN	25MG/ML	N09637 001
BP		50MG/ML	N09637 002
@		25MG/ML	N09637 001
@		50MG/ML	N09637 002
BP	STERIS	25MG/ML	N83759 001
BP		50MG/ML	N83759 002
@		25MG/ML	N83759 001
@		50MG/ML	N83759 002
	HYDROCORTONE		
BP	+ MERCK SHARP DOHME	50MG/ML	N08228 004
+		50MG/ML	N08228 004

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN			
+ GLAXO WELLCOME	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50218 001 AUG 09, 1985	
+ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50218 001 AUG 09, 1985	

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL

PANDEL			
+ SAVAGE LABS	0.1%	N20453 001 FEB 28, 1997	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE			
AP	ELKINS SINN	EQ 1GM BASE/VIAL	N87569 001	
	@	EQ 1GM BASE/VIAL	N87569 001	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROMORPHONE HCL			
> ADD >	AP	ABBOTT	10MG/ML	N74598 001 JUN 19, 1997	
> ADD >					
> DLT >	AP	SANOFI	10MG/ML	N74598 001 JUN 19, 1997	
> DLT >					

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

		HYDROXYZINE HCL			
> ADD >	AP	ABBOTT	25MG/ML	N87416 001	
> ADD >	AP		50MG/ML	N87546 001	
> DLT >	AP	STERLING WINTHROP	25MG/ML	N87416 001	
> DLT >	AP		50MG/ML	N87546 001	

TABLET; ORAL

	HYDROXYZINE HCL			
AB	HALSEY	25MG	N89117 001 MAY 02, 1988	> ADD >

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
	@ HALSEY	25MG	N89117 001 MAY 02, 1988	
AB	KV PHARM	10MG	N87819 001 JUN 23, 1982	
AB		25MG	N87820 001 JUN 23, 1982	
AB		50MG	N87821 001 JUN 23, 1982	
AB		100MG	N87822 001 JUN 23, 1982	
	@	10MG	N87819 001 JUN 23, 1982	
	@	25MG	N87820 001 JUN 23, 1982	
	@	50MG	N87821 001 JUN 23, 1982	
	@	100MG	N87822 001 JUN 23, 1982	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HY-PAM		
AB	EON	EQ 25MG HCL	N87479 001
	HYDROXYZINE PAMOATE		
AB	EON	EQ 25MG HCL	N87479 001

IBUPROFEN

SUSPENSION; ORAL

	IBU		
BX	KNOLL PHARM	100MG/5ML	N19784 001 DEC 18, 1989
	@	100MG/5ML	N19784 001 DEC 18, 1989

TABLET; ORAL

	IBUPROFEN			
AB	PUREPAC PHARM	800MG	N71964 001 FEB 01, 1988	
	@	800MG	N71964 001 FEB 01, 1988	
	MOTRIN			
AB	MCNEIL	300MG	N17463 003	> ADD >

IBUPROFEN

TABLET; ORAL
MOTRIN

> ADD >	AB		MCNEIL	400MG	N17463 002
> ADD >	AB			600MG	N17463 004
> ADD >	AB	+		800MG	N17463 005
> ADD >					MAY 22, 1985
> DLT >	AB		PHARMACIA AND UPJOHN	300MG	N17463 003
> DLT >	AB			400MG	N17463 002
> DLT >	AB			600MG	N17463 004
> DLT >	AB	+		800MG	N17463 005
> DLT >					MAY 22, 1985

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN PFS

+	PHARMACIA AND UPJOHN	1MG/ML	N50734 001
			FEB 17, 1997

IFOSFAMIDE

INJECTABLE; INJECTION
IFEX

+	BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001
			DEC 30, 1988
+		3GM/VIAL	N19763 002
			DEC 30, 1988
@		1GM/VIAL	N19763 001
			DEC 30, 1988
@		3GM/VIAL	N19763 002
			DEC 30, 1988

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT

+	BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003
			OCT 10, 1992
+		3GM/VIAL;100MG/ML	N19763 004
			OCT 10, 1992

IMIQUIMOD

CREAM; TOPICAL
ALDARA

+	3M	5%	N20723 001
			FEB 27, 1997

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB	MYLAN	1.25MG	N74461 002
			MAR 26, 1997
AB	NOVOPHARM	1.25MG	N74665 001
			APR 04, 1997
AB		2.5MG	N74665 002
			APR 04, 1997

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE

AMERSHAM	1mCi/ML	N19044 001
		DEC 23, 1985
MEDI PHYSICS	1mCi/ML	N19044 001
		DEC 23, 1985

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN

+	AKORN	25MG/VIAL	N11525 001
+		50MG/VIAL	N11525 002
+	BECTON DICKINSON	25MG/VIAL	N11525 001
+		50MG/VIAL	N11525 002

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270

> ADD >	NYCOMED	55%	N20808 001
> ADD >			AUG 29, 1997

VISIPAQUE 320

> ADD >	NYCOMED	65.2%	N20808 002
> ADD >			AUG 29, 1997

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

> DLT >		HIPPUTOPE		
> DLT >		BRACCO	1-2mCi/VIAL	N15419 002
> ADD >		@	1-2mCi/VIAL	N15419 002
> ADD >		IODOHIPPURATE SODIUM I 131		
> ADD >		@ CIS	0.2mCi/ML	N17313 001
> DLT >		SORIN	0.2mCi/ML	N17313 001

IOPAMIDOL

INJECTABLE; INJECTION

		IOPAMIDOL-250		
AP		FUJISAWA	51%	N74679 001 APR 02, 1997
		IOPAMIDOL-300		
AP		ABBOTT	61%	N74638 001 APR 30, 1997
AP		FUJISAWA	61%	N74679 002 APR 02, 1997
		IOPAMIDOL-300 IN PLASTIC CONTAINER		
AP		ABBOTT	61%	N74637 001 APR 03, 1997
		IOPAMIDOL-370		
AP		FUJISAWA	76%	N74679 003 APR 02, 1997
		ISOVUE-250		
AP	+	BRACCO	51%	N18735 007 JUL 06, 1992
AP	+		51%	N20327 002 OCT 12, 1994

IPODATE CALCIUM

> DLT >		GRANULE; ORAL		
> DLT >		ORAGRAFIN CALCIUM		
> DLT >		BRACCO	3GM/PACKET	N12968 001
> ADD >		@	3GM/PACKET	N12968 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

		ATROVENT		
AN	+	BOEHRINGER INGELHEIM	0.02%	N20228 001 SEP 29, 1993

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

		IPRATROPIUM BROMIDE		
AN		DEY	0.02%	N74755 001 JAN 10, 1997

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

		ISOETHARINE HCL		
> DLT >	AN	ALPHARMA	1%	N87101 001
> ADD >		@	1%	N87101 001

ISONIAZID

SYRUP; ORAL

		ISONIAZID		
AA	+	CAROLINA MEDCL	50MG/5ML	N88235 001 NOV 10, 1983
	+		50MG/5ML	N88235 001 NOV 10, 1983
AA		MIKART	50MG/5ML	N81118 001 JUL 21, 1997
		LANIAZID		
AA		LANNETT	50MG/5ML	N89243 001 FEB 03, 1986
		@	50MG/5ML	N89243 001 FEB 03, 1986

TABLET; ORAL

		ISONIAZID		
AA		MIKART	100MG	N40090 001 JUN 26, 1997
AA			300MG	N40090 002 JUN 26, 1997

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

		ISOPROTERENOL HCL		
BN	+	3M	0.12MG/INH	N10375 004
	+		0.12MG/INH	N10375 004
BN		ALPHARMA	0.12MG/INH	N85904 001
		@	0.12MG/INH	N85904 001

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
ISUPREL

AP	+ ABBOTT	0.2MG/ML	N10515 001	
AP	+ SANOFI WINTHROP	0.2MG/ML	N10515 001	

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX

+ JANSSEN	10MG/ML	N20657 001	FEB 21, 1997

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HCL

> ADD >	AP	ABBOTT	EQ 50MG BASE/ML	N74549 001 JUN 27, 1996
> ADD >	AP		EQ 100MG BASE/ML	N74549 002 JUN 27, 1996
> DLT >	AP	SANOFI WINTHROP	EQ 50MG BASE/ML	N74549 001 JUN 27, 1996
> DLT >	AP		EQ 100MG BASE/ML	N74549 002 JUN 27, 1996

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	ABBOTT	15MG/ML	N74801 001 JUN 05, 1997
AP		15MG/ML	N74802 001 JUN 05, 1997
AP		30MG/ML	N74801 002 JUN 05, 1997
AP		30MG/ML	N74802 002 JUN 05, 1997

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	MYLAN	10MG	N74761 001 MAY 16, 1997
AB	ROXANE	10MG	N74790 001 JUN 26, 1997

KETOROLAC TROMETHAMINE

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	TEVA	10MG	N74754 001 MAY 16, 1997

TORADOL

AB	+ SYNTEX	10MG	N19645 001 DEC 20, 1991

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

TAP HOLDINGS	15MG	N20406 001 MAY 10, 1995
+	30MG	N20406 002 MAY 10, 1995

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

TAP HOLDINGS	15MG	N20406 001 MAY 10, 1995
+	30MG	N20406 002 MAY 10, 1995

LETROZOLE

TABLET; ORAL
FEMARA

+ NOVARTIS	2.5MG	N20726 001 JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+ ABBOTT	EQ 10MG BASE/ML	N40147 001	JUN 25, 1997
AP	+ BEDFORD	EQ 200MG BASE/VIAL	N40056 001	MAY 23, 1995
	+	EQ 200MG BASE/VIAL	N40056 001	MAY 23, 1995
AP	GENSIA	EQ 350MG BASE/VIAL	N40174 001	JUN 12, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+	IMMUNEX	EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989
AP		PHARMACHEMIE	EQ 50MG BASE/VIAL	N89628 001	APR 17, 1997
AP			EQ 100MG BASE/VIAL	N89915 001	APR 17, 1997

TABLET; ORAL
LEUCOVORIN CALCIUM

> ADD >	AB	PAR PHARM	EQ 5MG BASE	N74544 001	AUG 28, 1997
> ADD >	AB		EQ 25MG BASE	N74544 002	AUG 28, 1997
> ADD >	AB	PHARMACHEMIE	EQ 5MG BASE	N73099 001	MAR 28, 1997
	AB		EQ 25MG BASE	N73101 001	MAR 28, 1997

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3

+	TAP HOLDINGS	11.25MG/VIAL	N20708 001	MAR 07, 1997

LUPRON DEPOT-4

+	TAP HOLDINGS	30MG/VIAL	N20517 002	MAY 30, 1997

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

> ADD >	AP	ABBOTT	1%	N40013 001	JUN 23, 1995
> ADD >	AP		2%	N40078 001	JUN 23, 1995
> DLT >	AP	SANOFI WINTHROP	1%	N40013 001	JUN 23, 1995
> DLT >	AP		2%	N40078 001	JUN 23, 1995

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHOBID

	SOLVAY	300MG	N18027 001	
+		300MG	N18027 001	

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

> ADD >	AP	ABBOTT	2MG/ML	N74243 001	APR 12, 1994
> ADD >	AP		2MG/ML	N74300 001	APR 12, 1994
> ADD >	AP		4MG/ML	N74243 002	APR 12, 1994
> ADD >	AP		4MG/ML	N74300 003	MAR 19, 1997
> DLT >	AP	STERLING WINTHROP	2MG/ML	N74243 001	APR 12, 1994
> DLT >	AP		2MG/ML	N74300 001	APR 12, 1994
> DLT >	AP		4MG/ML	N74243 002	APR 12, 1994

SOLUTION; ORAL
LORAZEPAM

+	ROXANE	0.5MG/5ML	N74648 001	MAR 18, 1997

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

	FUJISAWA	500MG/ML	N19316 001	SEP 08, 1986
+		500MG/ML	N19316 001	SEP 08, 1986

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	1GM/100ML	N20488 001	JUL 11, 1995
+		1GM/100ML	N20488 001	JUL 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	ABBOTT	4GM/100ML	N20309 001	JUN 24, 1994

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

	ABBOTT	80MG/ML		N20309 002 JUN 24, 1994
+		4GM/100ML		N20309 001 JUN 24, 1994
+		80MG/ML		N20309 002 JUN 24, 1994

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

AA	KV PHARM	12.5MG		N85524 001
AA		25MG		N85523 001
@		12.5MG		N85524 001
@		25MG		N85523 001
AA	VINTAGE PHARMS	12.5MG		N40179 001 JAN 30, 1997
AA		25MG		N40179 002 JAN 30, 1997

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
HUMEGON

AB	+ ORGANON	75 IU/VIAL;75 IU/VIAL		N20328 001 SEP 01, 1994
AB		75 IU/VIAL;75 IU/VIAL		N20328 001 SEP 01, 1994
AB	+	150 IU/VIAL;150 IU/VIAL		N20328 002 SEP 01, 1994
AB		150 IU/VIAL;150 IU/VIAL		N20328 002 SEP 01, 1994

REPRONAL

AB	FERRING	75 IU/VIAL;75 IU/VIAL		N73598 001 JAN 30, 1997
AB		75 IU/VIAL;75 IU/VIAL		N73598 001 JAN 30, 1997
AB		150 IU/VIAL;150 IU/VIAL		N73599 001 JAN 30, 1997
AB		150 IU/VIAL;150 IU/VIAL		N73599 001 JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	MALLINCKRODT	10MG/ML		N40163 001 MAY 12, 1997

TABLET; ORAL
MEPERIDINE HCL

AA	ROXANE	50MG		N40110 001 MAR 12, 1997
AA		100MG		N40110 002 MAR 12, 1997
AA	ROYCE LABS	50MG		N40186 001 JUN 30, 1997
AA		100MG		N40186 002 JUN 30, 1997

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	PUREPAC PHARM	200MG		N84804 001
AA		400MG		N84804 002
@		200MG		N84804 001
@		400MG		N84804 002

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

AA	JVL	10MG/5ML		N74702 001 MAR 24, 1997
AA	MORTON GROVE	10MG/5ML		N71656 001 OCT 13, 1987
AA		10MG/5ML		N74702 001 MAR 24, 1997
@		10MG/5ML		N71656 001 OCT 13, 1987

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

	BRISTOL MYERS SQUIBB	500MG		N20357 001 DEC 29, 1994

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE
+ BRISTOL MYERS SQUIBB 850MG N20357 002 DEC 29, 1994
500MG N20357 001 MAR 03, 1995
+ 850MG N20357 002 MAR 03, 1995

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION
PROVOCHOLINE
METHAPHARM 100MG/VIAL N19193 001 OCT 31, 1986
ROCHE 100MG/VIAL N19193 001 OCT 31, 1986

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE
AB APPLIED ANAL **25MG** **N40011 001** JUL 17, 1997
AB **50MG** **N40011 002** JUL 17, 1997

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL
AA PUREPAC PHARM **500MG** **N85718 001**
AA **750MG** **N85718 002**
@ 500MG N85718 001
@ 750MG N85718 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED
AP BRISTOL MYERS **EQ 25MG BASE/ML** **N89887 001** APR 14, 1989

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED
@ BRISTOL MYERS SQUIBB EQ 25MG BASE/ML N89887 001 APR 14, 1989

METHOXSALEN

CAPSULE; ORAL
OXSORALEN-ULTRA
+ ICN 10MG N19600 001 OCT 30, 1986

CAPSULE, LIQUID FILLED; ORAL
OXSORALEN-ULTRA
+ ICN 10MG N19600 001 OCT 30, 1986

METHYLDOPA

TABLET; ORAL
METHYLDOPA
AB HALSEY **125MG** **N71751 001** MAR 28, 1988
AB **250MG** **N71752 001** MAR 28, 1988
@ 125MG N71751 001 MAR 28, 1988
@ 250MG N71752 001 MAR 28, 1988
AB PUREPAC PHARM **125MG** **N70749 001** FEB 07, 1986
AB **250MG** **N70750 001** FEB 07, 1986
AB **500MG** **N70452 001** FEB 07, 1986
@ 125MG N70749 001 FEB 07, 1986
@ 250MG N70750 001 FEB 07, 1986
@ 500MG N70452 001 FEB 07, 1986

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HCL

> ADD >	**AB**	DANBURY PHARMA	**5MG**	**N40220 001**	AUG 29, 1997
> ADD >					
> ADD >	**AB**		**10MG**	**N40220 002**	AUG 29, 1997
> ADD >					
> ADD >	**AB**		**20MG**	**N40220 003**	AUG 29, 1997
> ADD >					

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

> ADD >	**AP**	ABBOTT	**EQ 5MG BASE/ML**	**N74147 001**	AUG 02, 1996
> ADD >					
	AP	FAULDING	**EQ 5MG BASE/ML**	**N71990 001**	JAN 18, 1989
	@		EQ 5MG BASE/ML	N71990 001	JAN 18, 1989
> DLT >	**AP**	SANOFI WINTHROP	**EQ 5MG BASE/ML**	**N74147 001**	AUG 02, 1996
> DLT >					

TABLET; ORAL
METOCLOPRAMIDE HCL

	AB	MUTUAL PHARM	**EQ 5MG BASE**	**N71536 002**	JAN 16, 1997

METOLAZONE

TABLET; ORAL
MYKROX

		MEDEVA	0.5MG	**N19532 001**	OCT 30, 1987
	+		0.5MG	N19532 001	OCT 30, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

> ADD >	**AP**	ABBOTT	**1MG/ML**	**N74133 001**	DEC 21, 1993
> ADD >					
> DLT >	**AP**	STERLING WINTHROP	**1MG/ML**	**N74133 001**	DEC 21, 1993
> DLT >					

METRONIDAZOLE

GEL; VAGINAL
METROGEL-VAGINAL

+	3M	0.75%	N20208 001	AUG 17, 1992
+	CURATEK	0.75%	N20208 001	AUG 17, 1992

INJECTABLE; INJECTION
METRONIDAZOLE

AP	STERIS	**500MG/100ML**	**N70042 001**	DEC 20, 1984
@		500MG/100ML	N70042 001	DEC 20, 1984

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	WATSON LABS	**150MG**	**N74711 001**	FEB 26, 1997
AB		**200MG**	**N74711 002**	FEB 26, 1997
AB		**250MG**	**N74711 003**	FEB 26, 1997

MIBEFRADIL DIHYDROCHLORIDE

TABLET; ORAL
POSICOR

	ROCHE	EQ 50MG BASE	N20689 001	JUN 20, 1997
+		EQ 100MG BASE	N20689 002	JUN 20, 1997

MICONAZOLE

INJECTABLE; INJECTION
MONISTAT

+	JANSSEN	10MG/ML	N18040 001	
@		10MG/ML	N18040 001	

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM
+ J AND J 2% N17494 001
+ JOHNSON RW 2% N17494 001

LOTION; TOPICAL
MONISTAT-DERM
@ J AND J 2% N17739 001
@ JOHNSON RW 2% N17739 001

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL
> DLT > LEDERLE EQ 50MG BASE N50451 003 AUG 10, 1982
> DLT > + EQ 100MG BASE N50451 002 AUG 10, 1982
> ADD > @ EQ 50MG BASE N50451 003 AUG 10, 1982
> ADD > @ EQ 100MG BASE N50451 002 AUG 10, 1982

MIRTAZAPINE

TABLET; ORAL
REMERON
+ ORGANON 30MG N20415 002 JUN 14, 1996
30MG N20415 002 JUN 14, 1996
+ 45MG N20415 003 MAR 17, 1997

MYCOPHENOLATE MOFETIL

TABLET; ORAL
CELLCEPT
+ SYNTEX 500MG N50723 001 JUN 19, 1997

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
> ADD > **AP** ABBOTT **0.02MG/ML** **N70171 001** SEP 24, 1986
> ADD > **AP** **0.4MG/ML** **N70172 001** SEP 24, 1986
> DLT > **AP** STERLING WINTHROP **0.02MG/ML** **N70171 001** SEP 24, 1986
> DLT > **AP** **0.4MG/ML** **N70172 001** SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES
AB ROYCE LABS **EQ 0.5MG BASE; EQ 50MG BASE** **N74736 001** JAN 21, 1997

TALWIN NX
AB + SANOFI **EQ 0.5MG BASE; EQ 50MG BASE** **N18733 001** DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE
AO STERIS **50MG/ML** **N87598 001** OCT 06, 1983
AO **100MG/ML** **N87599 001** OCT 06, 1983
@ 50MG/ML N87598 001 OCT 06, 1983
@ 100MG/ML N87599 001 OCT 06, 1983

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE
+ FISONS 1.75MG/INH N19660 001 DEC 30, 1992
+ RHONE POULENC RORER 1.75MG/INH N19660 001 DEC 30, 1992

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE
@ BRISTOL MYERS SQUIBB 50MG — N20152 001 DEC 22, 1994
\+ 50MG — N20152 001 DEC 22, 1994

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL
VIRACEPT
\+ AGOURON EQ 50MG BASE/SCOOPFUL — N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
\+ AGOURON EQ 250MG BASE — N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK **100%** — **N61579 001**
100% — N61579 001

NEOMYCIN SULFATE
AA PADDOCK **100%** — **N62385 001** JUN 01, 1982

NIACIN

TABLET; ORAL
NIACIN
AA HALSEY **500MG** — **N83453 001**
@ 500MG — N83453 001
AA PUREPAC PHARM **500MG** — **N83271 001**
@ 500MG — N83271 001

TABLET, EXTENDED RELEASE; ORAL
NIASPAN
\+ KOS 375MG — N20381 001 JUL 28, 1997
\+ 500MG — N20381 002 JUL 28, 1997

NIACIN

TABLET, EXTENDED RELEASE; ORAL
NIASPAN
\+ KOS 750MG — N20381 003 JUL 28, 1997
\+ 1GM — N20381 004 JUL 28, 1997

NIASPAN TITRATION STARTER PACK
\+ KOS 375MG;500MG;750MG — N20381 005 JUL 28, 1997

NICOTINE

INHALANT; INHALATION
NICOTROL
\+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE — N20714 001 MAY 02, 1997

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTION
AB MYLAN **100MG** — **N74967 002** JUL 09, 1997

NITROFURANTOIN
AB MYLAN **50MG** — **N74967 001** JUL 09, 1997

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED
\+ ABBOTT EQ 1MG BASE/ML — N07513 001
\+ SANOFI WINTHROP EQ 1MG BASE/ML — N07513 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
AB INVAMED **EQ 10MG BASE** — **N74835 001** JUN 30, 1997
AB **EQ 25MG BASE** — **N74835 002** JUN 30, 1997

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	INVAMED	EQ 50MG BASE	N74835 003	JUN 30, 1997
AB		EQ 75MG BASE	N74835 004	JUN 30, 1997

NYSTATIN

CREAM; TOPICAL

	MYKINAC			
	@ ALPHARMA	100,000 UNITS/GM	N62387 001	JUL 29, 1982
AT	NMC	100,000 UNITS/GM	N62387 001	JUL 29, 1982

OINTMENT; TOPICAL

	MYKINAC			
	@ ALPHARMA	100,000 UNITS/GM	N62731 001	SEP 22, 1986
AT	NMC	100,000 UNITS/GM	N62731 001	SEP 22, 1986

SUSPENSION; ORAL

	NYSTATIN			
AA	ALPHARMA	100,000 UNITS/ML	N62571 001	OCT 29, 1985
	@	100,000 UNITS/ML	N62571 001	OCT 29, 1985

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

	ZOFRAN			
	+ GLAXO WELLCOME	EQ 4MG BASE/5ML	N20605 001	JAN 24, 1997

OXACILLIN SODIUM

CAPSULE; ORAL

	BACTOCILL			
AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N61336 001	
AB	+	EQ 250MG BASE	N61336 001	
	OXACILLIN SODIUM			
AB	APOTHECON	EQ 250MG BASE	N61450 002	

OXACILLIN SODIUM

CAPSULE; ORAL

	OXACILLIN SODIUM			
AB	+ APOTHECON	EQ 500MG BASE	N61450 001	
	@	EQ 250MG BASE	N61450 002	
	@	EQ 500MG BASE	N61450 001	

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	CHOLEDYL SA			
	+ PARKE DAVIS	600MG	N86742 001	
	+ WARNER CHILCOTT	600MG	N86742 001	

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

	OXYBUTYNIN CHLORIDE			
AA	MORTON GROVE	5MG/5ML	N74868 001	FEB 12, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	OXYCONTIN			
	+ PURDUE FREDERICK	10MG	N20553 001	DEC 12, 1995
	+	20MG	N20553 002	DEC 12, 1995
	+	40MG	N20553 003	DEC 12, 1995
	+ PURDUE PHARMA	10MG	N20553 001	DEC 12, 1995
	+	20MG	N20553 002	DEC 12, 1995
	+	40MG	N20553 003	DEC 12, 1995
	+	80MG	N20553 004	JAN 06, 1997

OXYMETHOLONE

TABLET; ORAL

	ANADROL-50			
	+ SYNTEX	50MG	N16848 001	

OXYMETHOLONE

TABLET; ORAL
ANADROL-50
+ UNIMED 50MG N16848 001

OXYTOCIN

SOLUTION; NASAL
SYNTOCINON
+ NOVARTIS 40 USP UNITS/ML N12285 001
@ 40 USP UNITS/ML N12285 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AB + PARKE DAVIS **EQ 250MG BASE** **N60521 001**
AB **EQ 250MG BASE** **N62310 001**
PAROMOMYCIN SULFATE
AB CARACO **EQ 250MG BASE** N64171 001
JUN 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ SMITHKLINE BEECHAM EQ 10MG BASE/5ML N20710 001
JUN 25, 1997

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE
AB ESI LEDERLE **400MG** **N74877 001**
JUL 08, 1997
AB MYLAN **400MG** **N74425 001**
JUL 08, 1997
AB PUREPAC PHARM **400MG** **N74878 001**
JUL 09, 1997
TRENTAL
AB + HOECHST MARION RSSL **400MG** **N18631 001**
AUG 30, 1984

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
RHONE POULENC RORER 2MG N20184 001
DEC 30, 1993
4MG N20184 002
DEC 30, 1993
+ 8MG N20184 003
DEC 30, 1993
@ 2MG N20184 001
DEC 30, 1993
@ 4MG N20184 002
DEC 30, 1993
@ 8MG N20184 003
DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE
BC GRAHAM DM 105MG N87214 001
MAY 26, 1982
BC 105MG N88020 001
AUG 16, 1982
BC 105MG N88028 001
AUG 16, 1982
BC 105MG N88062 001
SEP 13, 1982
BC 105MG N88063 001
SEP 10, 1982
BC 105MG N88111 001
OCT 18, 1982
@ 105MG N87214 001
MAY 26, 1982
@ 105MG N88020 001
AUG 16, 1982
@ 105MG N88028 001
AUG 16, 1982
@ 105MG N88062 001
SEP 13, 1982
@ 105MG N88063 001
SEP 10, 1982
@ 105MG N88111 001
OCT 18, 1982

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
AA INWOOD LABS **35MG** **N84740 001**

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	INWOOD LABS	35MG	N84741 001	> ADD >	
AA		35MG	N84742 001	> ADD >	
AA		35MG	N84743 001		
@		35MG	N84740 001		
@		35MG	N84741 001		
@		35MG	N84742 001		
@		35MG	N84743 001		
AA	KV PHARM	35MG	N85525 001		
@		35MG	N85525 001		

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	30MG	N40227 001 JUN 18, 1997		
AA		37.5MG	N40228 001 JUN 19, 1997		
AA	KING PHARMS	30MG	N40083 001 MAR 07, 1997		

TABLET; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	37.5MG	N40190 001 MAY 30, 1997		

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

> ADD >	AP	ABBOTT	50MG/ML	N89744 001 DEC 18, 1987	> ADD >
> DLT >	AP	WINTHROP	50MG/ML	N89744 001 DEC 18, 1987	> DLT >

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

	PARKE DAVIS	30MG	N84349 001		
+		30MG	N84349 001		

PIMOZIDE

TABLET; ORAL
ORAP

	TEVA	1MG	N17473 003 AUG 27, 1997	> ADD >	

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	LEMMON	5MG	N74123 001 APR 17, 1997		
AB		10MG	N74123 002 APR 17, 1997		
AB	TEVA	5MG	N74123 001 APR 17, 1997		
AB		10MG	N74123 002 APR 17, 1997		

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	EGIS	10MG	N74808 001 JUL 08, 1997		
AB		20MG	N74808 002 JUL 08, 1997		

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001 MAR 13, 1997		

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

AT	+ ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N50567 001 OCT 20, 1988		

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		BAUSCH AND LOMB	10,000 UNITS/ML; EQ 1MG BASE/ML	N64120 001 FEB 14, 1997

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	+	ABBOTT	745MG/100ML	N20161 001 NOV 30, 1992
AP	+		14.9MG/ML	N20161 005 NOV 30, 1992
	@		745MG/100ML	N20161 001 NOV 30, 1992
	@		14.9MG/ML	N20161 005 NOV 30, 1992
AP	+	BAXTER HLTHCARE	746MG/100ML	N19904 005 DEC 17, 1990
AP	+		14.9MG/ML	N19904 001 DEC 26, 1989
	+		746MG/100ML	N19904 005 DEC 17, 1990
	+		14.9MG/ML	N19904 001 DEC 26, 1989

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	ABBOTT	1.49GM/100ML	N20161 002 NOV 30, 1992
	@		1.49GM/100ML	N20161 002 NOV 30, 1992
AP	+	BAXTER HLTHCARE	1.49GM/100ML	N19904 006 DEC 17, 1990
	+		1.49GM/100ML	N19904 006 DEC 17, 1990

PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE

TABLET; ORAL
MIRAPEX

	+	PHARMACIA AND UPJOHN	0.125MG	N20667 001 JUL 01, 1997
			0.25MG	N20667 002 JUL 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE

TABLET; ORAL
MIRAPEX

		PHARMACIA AND UPJOHN	1MG	N20667 003 JUL 01, 1997
	@		1.25MG	N20667 004 JUL 01, 1997
	+		1.5MG	N20667 005 JUL 01, 1997

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX		PUREPAC PHARM	5MG	N80325 001
	@		5MG	N80325 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

		STERIS	25MG/ML	N83654 001
	@		25MG/ML	N83654 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PEDIAPRED

	+	PISONS	EQ 5MG BASE/5ML	N19157 001 MAY 28, 1986
	+	MEDEVA	EQ 5MG BASE/5ML	N19157 001 MAY 28, 1986

PREDNISONE

TABLET; ORAL
PREDNISONE

AB		HALSEY	5MG	N80300 001
	@		5MG	N80300 001

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

> ADD >	**AP**	ABBOTT	**500MG/ML**	**N89537 001**	
> ADD >				AUG 25, 1987	
> DLT >	**AP**	WINTHROP	**500MG/ML**	**N89537 001**	
> DLT >				AUG 25, 1987	

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB	INWOOD LABS	**500MG**	**N89840 001**	
			MAR 06, 1989	
@		500MG	N89840 001	
			MAR 06, 1989	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVOCAIN

> ADD >	**AP**	+ ABBOTT	**1%**	**N85362 003**	
> ADD >	**AP**	+	**2%**	**N85362 004**	
> ADD >		+	10%	N86797 001	
> DLT >	**AP**	+ STERLING WINTHROP	**1%**	**N85362 003**	
> DLT >	**AP**	+	**2%**	**N85362 004**	
> DLT >		+	10%	N86797 001	

PROCAINE HCL

AP	STERIS	**1%**	**N83535 001**	
AP		**2%**	**N83535 002**	
@		1%	N83535 001	
@		2%	N83535 002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

> DLT >	INJECTABLE; INJECTION			
> DLT >	TETRACYN			
> DLT >	+ PFIZER	40MG/VIAL;250MG/VIAL	N60285 003	
> ADD >	@	40MG/VIAL;250MG/VIAL	N60285 003	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

> ADD >	**AP**	ABBOTT	**EQ 5MG BASE/ML**	**N89703 001**
> ADD >				APR 07, 1988

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	STERIS	**EQ 5MG BASE/ML**	**N89605 001**	
			JUL 08, 1987	
@		EQ 5MG BASE/ML	N89605 001	
			JUL 08, 1987	
> DLT > **AP**	STERLING WINTHROP	**EQ 5MG BASE/ML**	**N89703 001**	
> DLT >			APR 07, 1988	

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	DURAMED	**EQ 5MG BASE**	**N40207 001**
			MAY 01, 1997
AB		**EQ 10MG BASE**	**N40207 002**
			MAY 01, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

	COLUMBIA RES LABS	4%	N20701 001
			JUL 31, 1997
+		8%	N20701 002
			JUL 31, 1997
+		8%	N20756 001
			MAY 13, 1997

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

> ADD > **AP**	ABBOTT	**50MG/ML**	**N83838 002**	
AP	STERIS	**25MG/ML**	**N83532 001**	
AP		**50MG/ML**	**N83532 002**	
@		25MG/ML	N83532 001	
@		50MG/ML	N83532 002	
> DLT > **AP**	STERLING WINTHROP	**50MG/ML**	**N83838 002**	

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

BP	PAR PHARM	15MG	N88377 001	> ADD >	
			DEC 08, 1983	> DLT >	
	@	15MG	N88377 001		
			DEC 08, 1983		

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	ROXANE	32MG	N83089 001	> ADD >	
AA		65MG	N83089 002	> DLT >	
	@	32MG	N83089 001		
	@	65MG	N83089 002		

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ROXANE	10MG	N70516 001		
			JUL 07, 1986		
AB		20MG	N70517 001		
			JUL 07, 1986		
AB		40MG	N70518 001		
			JUL 07, 1986		
AB		60MG	N70519 001		
			SEP 24, 1986		
AB		80MG	N70520 001		
			JUL 07, 1986		
AB		90MG	N70521 001		
			SEP 24, 1986	> ADD >	
	@	10MG	N70516 001	> ADD >	
			JUL 07, 1986	> ADD >	
	@	20MG	N70517 001	> ADD >	
			JUL 07, 1986	> ADD >	
	@	40MG	N70518 001	> ADD >	
			JUL 07, 1986	> ADD >	
	@	60MG	N70519 001	> ADD >	
			SEP 24, 1986	> ADD >	
	@	80MG	N70520 001	> ADD >	
			JUL 07, 1986	> ADD >	
	@	90MG	N70521 001	> ADD >	
			SEP 24, 1986		

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

AP	+ ICN	5MG/ML	N09830 001		
AP	* ROCHE	5MG/ML	N09830 001		

SYRUP; ORAL
MESTINON

	+ ICN	60MG/5ML	N15193 001	> ADD >	
	* ROCHE	60MG/5ML	N15193 001	> DLT >	

TABLET; ORAL
MESTINON

	+ ICN	60MG	N09829 002		
	* ROCHE	60MG	N09829 002		

TABLET, EXTENDED RELEASE; ORAL
MESTINON

	+ ICN	180MG	N11665 001	> ADD >	
	* ROCHE	180MG	N11665 001	> DLT >	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

AP	STERIS	100MG/ML	N83760 001
	@	100MG/ML	N83760 001

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662 001		
			AUG 29, 1997		
AB		EQ 300MG BASE	N74662 002		
			AUG 29, 1997		
AB	GENEVA PHARMS	EQ 150MG BASE	N74467 001		
			AUG 29, 1997		
AB		EQ 300MG BASE	N74467 002		
			AUG 29, 1997		
AB	GENPHARM	EQ 150MG BASE	N74023 001		
			AUG 22, 1997		
AB		EQ 300MG BASE	N74023 002		
			AUG 22, 1997		
AB	GRANUTEC PHARMS	EQ 150MG BASE	N74488 001		
			JUL 31, 1997		

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB		GRANUTEC PHARMS	**EQ 300MG BASE**	**N74488 002** JUL 31, 1997

ZANTAC 150

AB		GLAXO WELLCOME	**EQ 150MG BASE**	**N18703 001** JUN 09, 1983

ZANTAC 300

AB	+	GLAXO WELLCOME	**EQ 300MG BASE**	**N18703 002** DEC 09, 1985

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUVAL

>DLT<	BP	+	PAL PAK	100MG	N09108 004
>ADD<		+		100MG	N09108 004

RAUWOLFIA SERPENTINA

>DLT<	BP		GLOBAL PHARM	50MG	N09273 001
>DLT<	BP			100MG	N09273 002
>ADD<		@		50MG	N09273 001
>ADD<		@		100MG	N09273 002
		@	ZENITH GOLDLINE	50MG	N11521 001
		@		100MG	N11521 002
		@	ZENITH LABS	50MG	N11521 001
		@		100MG	N11521 002

RESERPINE

TABLET; ORAL
RESERPINE

BP		PUREPAC PHARM	0.1MG	N80753 002
BP			0.25MG	N80753 001
	@		0.1MG	N80753 002
	@		0.25MG	N80753 001
	@	ZENITH GOLDLINE	0.1MG	N11185 001
	@		0.25MG	N11185 002
	@	ZENITH LABS	0.1MG	N11185 001
	@		0.25MG	N11185 002

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

AB	EON	**300MG**	**N64150 001** MAY 28, 1997

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

CYTOGEN	50mCi/ML	N20570 001 MAR 28, 1997

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

AA	HALSEY	**100MG**	**N84676 001**
	@	100MG	N84676 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL

AB	+	SOMERSET	**5MG**	**N20647 001** MAY 15, 1996
	+		5MG	N20647 001 MAY 15, 1996

TABLET; ORAL
SELEGILINE HCL

AB		APOTEX	**5MG**	**N74871 001** JUN 06, 1997
AB		APOTHECON	**5MG**	**N74672 001** APR 01, 1997
AB		TEVA	**5MG**	**N74744 001** JAN 27, 1997

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>ADD<	**AP**	ABBOTT	**9MG/ML**	**N19465 002**
>ADD<				JUL 15, 1985

SODIUM IODIDE, I-123

CAPSULE; ORAL
SODIUM IODIDE I 123

AA	GOLDEN PHARMS	100 uCi	N18671 001 MAY 27, 1982	> DLT >	
AA		100 uCi	N18671 001 MAY 27, 1982	> DLT	
AA		200 uCi	N18671 002 MAY 27, 1982		
AA		200 uCi	N18671 002 MAY 27, 1982		

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

AP	ABBOTT	50MG/VIAL	N71555 001 NOV 16, 1987	> ADD >	
	@	50MG/VIAL	N71555 001 NOV 16, 1987	> ADD >	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
NORDITROPIN

BX	+ NOVO NORDISK	4MG/VIAL	N19721 001 MAY 08, 1995	> ADD >	

SEROSTIM

BX	SERONO	4MG/VIAL	N20604 003 JUL 25, 1997	> ADD >	

SULFAMETHOXAZOLE

SUSPENSION; ORAL
GANTANOL

	+ ROCHE	500MG/5ML	N13664 002	> ADD >	
	@	500MG/5ML	N13664 002	> ADD >	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

> ADD >	AP	ABBOTT	80MG/ML;16MG/ML	N73199 001 SEP 11, 1992	
> ADD >					

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	STERLING WINTHROP	80MG/ML;16MG/ML	N73199 001 SEP 11, 1992		

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

AB	PUREPAC PHARM	500MG	N80087 001		
	@	500MG	N80087 001		

SUMATRIPTAN

SPRAY; NASAL
IMITREX

	GLAXO WELLCOME	5MG/SPRAY	N20626 001 AUG 26, 1997	> ADD >	
		10MG/SPRAY	N20626 002 AUG 29, 1997	> ADD >	
	+	20MG/SPRAY	N20626 003 AUG 26, 1997	> ADD >	

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX

	+ ZENECA	EQ 10MG BASE	N17970 001		
		EQ 10MG BASE	N17970 001		

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX

	+ BOEHRINGER INGELHEIM	0.4MG	N20579 001 APR 15, 1997		

TAZAROTENE

GEL; TOPICAL
TAZORAC

	ALLERGAN	0.05%	N20600 001 JUN 13, 1997		

TAZAROTENE

GEL; TOPICAL
TAZORAC
+ ALLERGAN 0.1% N20600 002
JUN 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
AN-MAA
> ADD > @ CIS N/A N17792 001
> DLT > BS SORIN N/A N17792 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-BRACCO
AP BRACCO **N/A** **N18107 001**
MDP-SQUIBB
AP BRACCO **N/A** **N18107 001**

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
MIRALUMA
DUPONT N/A N19785 003
MAY 23, 1997

TERFENADINE

TABLET; ORAL
SELDANE
AB + HOECHST MARION RSSL **60MG** **N18949 001**
MAY 08, 1985
TERFENADINE
AB BAKER NORTON **60MG** **N74475 001**
JAN 03, 1997

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB WARNER CHILCOTT **250MG** **N62300 001**

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB WARNER CHILCOTT **500MG** **N62300 002**
@ 250MG N62300 001
@ 500MG N62300 002

INJECTABLE; INJECTION
ACHROMYCIN
AP + LEDERLE **250MG/VIAL** **N50273 002**
AP **500MG/VIAL** **N50273 003**
+ 250MG/VIAL N50273 002
500MG/VIAL N50273 003

TETRACYN
AP PFIZER **250MG/VIAL** **N60096 001**
AP **500MG/VIAL** **N60096 002**
@ 250MG/VIAL N60096 001
@ 500MG/VIAL N60096 002

SUSPENSION; ORAL
TETRACYCLINE HCL
AB ALPHARMA **125MG/5ML** **N60633 001**
@ 125MG/5ML N60633 001
AB PUREPAC PHARM **125MG/5ML** **N60291 001**
@ 125MG/5ML N60291 001
TETRACYN
AB PFIPHARMECS **125MG/5ML** **N60095 001**
@ 125MG/5ML N60095 001

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
AP DUPONT **1mCi/ML** **N17806 001**
AP + **1mCi/ML** **N17806 001**
AP MALLINCKRODT **1mCi/ML** **N18150 001**
AP + **1mCi/ML** **N18150 001**
AP + MEDI PHYSICS **1mCi/ML** **N18110 002**
FEB 27, 1996
1mCi/ML N18110 002
FEB 27, 1996

THEOPHYLLINE

CAPSULE; ORAL
BRONKODYL
BP STERLING WINTHROP 100MG N85264 001

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

BP	STERLING WINTHROP	200MG	N85264 002	> ADD >
@		100MG	N85264 001	> ADD >
@		200MG	N85264 002	

THEOPHYLLINE

BP	KV PHARM	100MG	N85263 001	
BP		200MG	N85263 002	
@		100MG	N85263 001	> DLT >
@		200MG	N85263 002	> DLT >
				> DLT >
				> ADD >

CAPSULE, EXTENDED RELEASE; ORAL

SOMOPHYLLIN-CRT

BC	GRAHAM DM	50MG	N87763 001
			FEB 27, 1985
BC		100MG	N87194 001
BC		200MG	N88382 001
			FEB 27, 1985
BC		250MG	N87193 001
BC		300MG	N88383 001
			FEB 27, 1985
@		50MG	N87763 001
			FEB 27, 1985
@		100MG	N87194 001
@		200MG	N88382 001
			FEB 27, 1985
@		250MG	N87193 001
@		300MG	N88383 001
			FEB 27, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

> ADD >	AP	ABBOTT	100MG/ML	N40079 001	
> ADD >				MAY 03, 1996	
> DLT >	AP	SANOFI WINTHROP	100MG/ML	N40079 001	
> DLT >				MAY 03, 1996	
	AP	STERIS	100MG/ML	N83534 001	
			200MG/ML	N83534 002	
	@		100MG/ML	N83534 001	
	@		200MG/ML	N83534 002	

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HCL

AA	PHARM ASSOC	30MG/ML	N40187 001	
			AUG 28, 1997	

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

+	ARMOUR PHARM	10 IU/VIAL	N08682 001
@	RHONE POULENC	10 IU/VIAL	N08682 001

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+	SANOFI	EQ 200MG BASE	N20707 001
			MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+	LEIRAS	EQ 0.25% BASE	N20439 001
			MAR 31, 1995
+		EQ 0.5% BASE	N20439 002
			MAR 31, 1995
+	OY STAR	EQ 0.25% BASE	N20439 001
			MAR 31, 1995
+		EQ 0.5% BASE	N20439 002
			MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT	ADV REMEDIES	EQ 0.25% BASE	N74465 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74466 001
			MAR 25, 1997
AT	AKORN	EQ 0.25% BASE	N74515 001
			MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	AKORN	**EQ 0.5% BASE**	**N74516 001**	MAR 25, 1997
AT	BAUSCH AND LOMB	**EQ 0.25% BASE**	**N74778 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74776 001**	MAR 25, 1997
AT	FOUGERA	**EQ 0.25% BASE**	**N74667 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74668 001**	MAR 25, 1997
AT	PACIFIC PHARMA	**EQ 0.25% BASE**	**N74746 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74747 001**	MAR 25, 1997

TIOCONAZOLE

OINTMENT; VAGINAL

	VAGISTAT-1		
+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE		
AB	PUREPAC PHARM	**500MG**	**N88950 001** JUN 17, 1985
@		500MG	N88950 001 JUN 17, 1985

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM		
AB	BAKER NORTON	**EQ 600MG BASE**	**N74399 001** MAR 28, 1996
AB	LEMMON	**EQ 600MG BASE**	**N74729 001** FEB 27, 1997
@	TEVA	EQ 600MG BASE	N74729 001 FEB 27, 1997

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM		
AB	ZENITH GOLDLINE	**EQ 600MG BASE**	**N74399 001** MAR 28, 1996

TOPIRAMATE

TABLET; ORAL

	TOPAMAX		
@	JOHNSON RW	400MG	N20505 006 DEC 24, 1996

TOREMIFENE CITRATE

TABLET; ORAL

	FARESTON		
+	ORION	EQ 60MG BASE	N20497 001 MAY 29, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	TRAZODONE HCL		
AB	TEVA	**150MG**	**N74357 001** APR 30, 1997

TRETINOIN

CREAM; TOPICAL

	AVITA		
AB	PENEDERM	**0.025%**	**N20404 003** JAN 14, 1997
	RETIN-A		
AB +	J AND J	**0.025%**	**N19049 001** SEP 16, 1988

GEL; TOPICAL

	RETIN-A MICRO		
+	ADV POLYMER	0.1%	N20475 001 FEB 07, 1997

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE

BP	PUREPAC PHARM	2MG	N84020 002		
BP		4MG	N84020 003		
@		2MG	N84020 002		
@		4MG	N84020 003		

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	ALPHARMA	0.1%	N87192 001 SEP 08, 1982	> DLT >	
@		0.1%	N87192 001 SEP 08, 1982		

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE

BP	STERIS	40MG/ML	N85529 001		
@		40MG/ML	N85529 001		

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	MYLAN	EQ 1MG BASE	N40209 001 JUL 07, 1997		
AB		EQ 2MG BASE	N40209 002 JUL 07, 1997		
AB		EQ 5MG BASE	N40209 003 JUL 07, 1997		
AB		EQ 10MG BASE	N40209 004 JUL 07, 1997	> ADD > > ADD >	

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE

+	LEDERLE	5MG	N12947 001	> ADD >	
@		5MG	N12947 001	> ADD >	

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL
TRIHEXYPHENIDYL HCL

AA	PHARM ASSOC	2MG/5ML	N40177 001 APR 17, 1997		

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL

AP	ABBOTT	100MG/ML	N88804 001 APR 03, 1987	> ADD > > ADD >	
AP	STERLING WINTHROP	100MG/ML	N88804 001 APR 03, 1987	> DLT > > DLT >	

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM

AB	GLAXO WELLCOME	200MG	N17943 003 JUL 14, 1982		
AB	+	200MG	N17943 003 JUL 14, 1982		

TRIMPEX 200

AB	+ ROCHE	200MG	N17952 002 NOV 09, 1982		
@		200MG	N17952 002 NOV 09, 1982		

TROGLITAZONE

TABLET; ORAL
PRELAY

AB	SANKYO	200MG	N20719 001 JAN 29, 1997		
AB		300MG	N20719 003 AUG 04, 1997	> ADD > > ADD >	
AB		400MG	N20719 002 JAN 29, 1997		

REZULIN

AB	PARKE DAVIS	200MG	N20720 001 JAN 29, 1997		
AB		300MG	N20720 003 AUG 04, 1997	> ADD >	

TROGLITAZONE

TABLET; ORAL

	REZULIN			
AB	PARKE DAVIS	400MG	N20720 002	JAN 29, 1997

UREA C-14

CAPSULE; ORAL

	PYTEST			
+	TRI MED SPECLTS	1 uCi	N20617 001	MAY 09, 1997
	PYTEST KIT			
+	TRI MED SPECLTS	1 uCi	N20617 002	MAY 09, 1997

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	VANCOCIN HCL IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001	APR 29, 1993
+	LILLY	EQ 500MG BASE/100ML	N50671 001	APR 29, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	VERAPAMIL HCL			
> ADD > AP	ABBOTT	2.5MG/ML	N70577 001	FEB 02, 1987
> ADD >				
> DLT > AP	STERLING WINTHROP	2.5MG/ML	N70577 001	FEB 02, 1987
> DLT >				

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR			
AB +	KNOLL PHARM	120MG	N19152 003	MAR 06, 1991
	VERAPAMIL HCL			
AB	MYLAN	120MG	N74587 002	FEB 21, 1997

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCREX			
AP +	BRISTOL MYERS	5MG/VIAL	N70867 001	JUL 12, 1988
@	BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001	JUL 12, 1988
	VINCRISTINE SULFATE			
AP	FAULDING	5MG/VIAL	N71561 001	APR 11, 1988
+		5MG/VIAL	N71561 001	APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN			
AB	DUPONT MERCK	1MG	N09218 022	MAR 01, 1990
AB +		2MG	N09218 013	
AB		2.5MG	N09218 018	
AB		4MG	N09218 023	AUG 24, 1993
AB		5MG	N09218 007	
AB		7.5MG	N09218 016	
AB +		10MG	N09218 005	
	WARFARIN SODIUM			
AB	BARR	1MG	N40145 001	MAR 26, 1997
AB		2MG	N40145 002	MAR 26, 1997
AB		2.5MG	N40145 003	MAR 26, 1997
AB		4MG	N40145 004	MAR 26, 1997
AB		5MG	N40145 005	MAR 26, 1997
AB		7.5MG	N40145 006	MAR 26, 1997
AB		10MG	N40145 007	MAR 26, 1997

ZINC ACETATE

CAPSULE; ORAL

GALZIN			
TEVA		EQ 25MG ZINC	N20458 001 JAN 28, 1997
+		EQ 50MG ZINC	N20458 002 JAN 28, 1997

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV				
+ GRAHAM DM	12MG;75MG	N18793 001	> DLT >	
		APR 25, 1985	> DLT >	
@	12MG;75MG	N18793 001	> ADD >	
		APR 25, 1985	> ADD >	
COLD CAPSULE V				
GRAHAM DM	8MG;75MG	N18794 001		
		APR 23, 1985		
@	8MG;75MG	N18794 001		
		APR 23, 1985		

TABLET, EXTENDED RELEASE; ORAL

CONTAC				
NOVARTIS	12MG;75MG	N19613 001		
		JUN 13, 1986		
PHENYLPROPANOLAMINE HCL/CHLORPHENIRAMINE				
SANDOZ	12MG;75MG	N19613 001		

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12				
+ CENT PHARMS	12MG;120MG	N18935 001		
		APR 15, 1985		
@ SCHWARZ PHARMA	12MG;120MG	N18935 001		
		APR 15, 1985		
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE				
KV PHARM	12MG;120MG	N71455 001		
		MAR 01, 1989		
@	12MG;120MG	N71455 001	> DLT >	
		MAR 01, 1989	> DLT >	
			> ADD >	
			> ADD >	

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE			> DLT >	
LEMMON	1.34MG	N73282 002	> DLT >	
		DEC 03, 1992	> ADD >	
TEVA	1.34MG	N73282 002	> ADD >	
		DEC 03, 1992		

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN AF				
+ SCHERING PLOUGH	1%	N17619 002		
		OCT 27, 1989		
+	1%	N20888 001		
		OCT 27, 1989		

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK		
+ SCHERING PLOUGH	1%,200MG	N20526 002
		JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK		
+ SCHERING PLOUGH	1%,100MG	N20289 002
		APR 26, 1993
MYCELEX-7 COMBINATION PACK		
BAYER	1%,100MG	N20389 002
		JUN 23, 1994

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK		
+ SCHERING PLOUGH	1%,200MG	N20526 002
		JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK		
+ SCHERING PLOUGH	1%,100MG	N20289 002
		APR 26, 1993
MYCELEX-7 COMBINATION PACK		
BAYER	1%,100MG	N20389 002
		JUN 23, 1994

LOTION; TOPICAL

LOTRIMIN AF		
+ SCHERING	1%	N18813 002
		OCT 27, 1989
+ SCHERING PLOUGH	1%	N20889 001
		OCT 27, 1989

SOLUTION; TOPICAL

LOTRIMIN AF		
+ SCHERING PLOUGH	1%	N17613 002
		OCT 27, 1989
+	1%	N20890 001
		OCT 27, 1989

SUPPOSITORY; VAGINAL

GYNE-LOTRIMIN		
+ SCHERING PLOUGH	100MG	N17717 002
		NOV 30, 1990

CLOTRIMAZOLE

SUPPOSITORY; VAGINAL
GYNE-LOTRIMIN 3
+ SCHERING PLOUGH 200MG N20525 001 JUL 29, 1996

MYCELEX-7
BAYER 100MG N18182 002 DEC 26, 1991

TABLET; VAGINAL
GYNE-LOTRIMIN
+ SCHERING PLOUGH 100MG N17717 002 NOV 30, 1990

GYNE-LOTRIMIN 3
+ SCHERING PLOUGH 200MG N20525 001 JUL 29, 1996

MYCELEX-7
BAYER 100MG N18182 002 DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL
NASALCROM
+ PHARMACIA AND UPJOHN 5.2MG/SPRAY N20463 001 JAN 03, 1997 > ADD >

IBUPROFEN

TABLET; ORAL
IBUPROFEN
PUREPAC PHARM 200MG N71122 001 OCT 03, 1986
200MG N71664 001 FEB 03, 1987
@ 200MG N71122 001 OCT 03, 1986
@ 200MG N71664 001 FEB 03, 1987

JUNIOR STRENGTH MOTRIN
MCNEIL 100MG N20602 001 JUN 10, 1996
+ 100MG N20602 001 JUN 10, 1996

NUPRIN
@ MCNEIL 200MG N19012 001 MAY 18, 1984

IBUPROFEN

TABLET; ORAL
NUPRIN
@ MCNEIL 200MG N19012 003 JUL 29, 1987
@ PHARMACIA AND UPJOHN 200MG N19012 001 MAY 18, 1984
@ 200MG N19012 003 JUL 29, 1987

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
VELOSULIN BR HUMAN
+ NOVO NORDISK 100 UNITS/ML N19450 001 MAY 30, 1986

VELOSULIN HUMAN
+ NOVO NORDISK 100 UNITS/ML N19450 001 MAY 30, 1986

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
MORTON GROVE 1MG/5ML N74730 001 AUG 28, 1997 > ADD >

TABLET, CHEWABLE; ORAL
IMODIUM A-D
+ MCNEIL 2MG N20448 001 JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL
IMODIUM ADVANCED
+ MCNEIL 2MG;125MG N20606 001 JUN 26, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE
PERRIGO 2% N74760 001 MAY 15, 1997

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

	TARO	2%	N74444 001 JAN 13, 1997

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK

	ALPHARMA	2%,100MG	N74586 001 JUL 17, 1997

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

	G AND W LABS	100MG	N74414 001 APR 30, 1997
+	PERRIGO	100MG	N74395 001 MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

	MORTON GROVE	2%	N74767 001 FEB 28, 1997

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

	GRANUTEC	EQ 200MG BASE	N74635 001 JAN 13, 1997
	INVAMED	EQ 200MG BASE	N74646 001 JAN 13, 1997
	NOVOPHARM	EQ 200MG BASE	N74635 001 JAN 13, 1997
	PERRIGO	EQ 200MG BASE	N74661 001 JAN 13, 1997
	PVT FORM	EQ 200MG BASE	N74789 001 FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL
NIX

+	WARNER LAMBERT	1%	N19918 001 MAY 02, 1990

PERMETHRIN

LOTION; TOPICAL
NIX

+	WARNER WELLCOME	1%	N19918 001 MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

	KV PHARM	120MG;5MG	N71798 001 MAR 16, 1989
	@	120MG;5MG	N71798 001 MAR 16, 1989

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL

+	COLGATE PALMOLIVE	0.24%;0.3%	N20231 001 JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+	BRISTOL MYERS SQUIBB	6.5%	N20676 001 FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 8/ AUGUST '97

NO AUGUST 1997 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Star, Robert A., M.D. UT-Southwestern Medical School 5323 Harry Hines Dallas, TX 75235 DD=08/19/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Busulfan TN=	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg, MD 20877 DD=08/19/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Diazepam viscous solution for rectal administration TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco, CA 94080 DD=02/25/1992 MA=07/29/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Sreet Suite 8J New York, NY 10019 DD=06/02/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997
Lepirudin TN= Refludan	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corporation 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997 MA=08/04/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross, GA 30092 DD=08/05/1997
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Recombinant human acid alpha-glucosidase TN=	Treatment of glycogen storage disease type II.	Chen, Y.T., M.D., Ph.D. Department of Pediatrics Duke University Medical Center Durham, NC 27710 DD=08/19/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Short chain fatty acid enema TN= Colomed	Treatment of chronic radiation proctitis.	Orphan Medical, Inc. 13911 Ridgedale Drive, Suite 475 Minnetonka, MN 55305 DD=08/19/1997

Orphan Product Designations and Approvals List
January 1997 through August 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN

NEW INDICATION

I-177	TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUGAFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THNNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN ARECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OF A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSIS SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTRURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-198	TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020059	001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
020291	001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
			5439670	JUL 06, 2010			
			5605674	FEB 25, 2014			
020560	001	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
						I-187	APR 25, 2000
020560	002	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
						I-187	APR 25, 2000
020560	003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
			4621077	NOV 04, 2003	U-114	I-185	APR 25, 2000
						I-187	APR 25, 2000
020221	001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
			5591731	JUL 31, 2012			
020333	001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						NCE	MAR 14, 2002
020333	002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						NCE	MAR 14, 2002
020227	002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
			5273995	DEC 28, 2010	U-162		
			5385929	MAY 04, 2014	U-59		
020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
			5273995	DEC 28, 2010	U-162		
			5385929	MAY 04, 2014	U-59		
020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
			5273995	DEC 28, 2010	U-162		
			5385929	MAY 04, 2014	U-59		
020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
020032	001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020619	001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
020490	001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
						NCE	SEP 06, 2001
020535	002	BROMFENAC SODIUM;DURACT				NCE	JUL 15, 2002
020441	002	BUDESONIDE;PULMICORT	4907583	MAR 13, 2002			
			4524769	JUN 25, 2002			
			4668218	APR 11, 2006			
020441	003	BUDESONIDE;PULMICORT	4907583	MAR 13, 2002			
			4524769	JUN 25, 2002			
			4668218	APR 11, 2006			
018644	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
018644	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
			5427798	AUG 12, 2013			
			RE33994	AUG 18, 2004			
020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
			5427798	AUG 12, 2013			
			RE33994	AUG 18, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177		
	019881	001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
	020664	001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
	020273	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
	020554	001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NDF	MAR 03, 2000
							NCE	DEC 29, 1998
	019880	001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	020297	001	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297	002	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297	003	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297	004	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020740	001	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	020740	002	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	020740	003	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	020740	004	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020519	001	CICLOPIROX;LOPROX				NDF	JUL 21, 2000
	019537	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011		I-188	JUN 03, 2000
				4670444	DEC 09, 2003	U-36		
	019537	002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019537	003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019537	004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019847	001	CIPROFLOXACIN;CIPRO	4705789	NOV 10, 2004		I-179	OCT 21, 1999
>ADD>							I-201	AUG 07, 2000
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
>ADD>							I-201	AUG 07, 2000
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
>ADD>							I-201	AUG 07, 2000
	017533	001	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	002	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	003	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	005	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	006	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	020463	001	CROMOLYN SODIUM;NASALCROM				NP	JAN 03, 2000
	020430	001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
	020705	001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
				5482931	JUN 29, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
				5482931	JUN 29, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019955	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
019955	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
020648	001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
						ODE	JUL 29, 2004
020648	002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
						ODE	JUL 29, 2004
020648	003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
						ODE	JUL 29, 2004
020648	004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
						ODE	JUL 29, 2004
020648	005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
						ODE	JUL 29, 2004
020037	001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
			4829088	APR 14, 2007			
020154	002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
020154	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
020156	001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
018723	001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
018723	002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
018723	003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
019680	001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008		I-181	JUN 20, 1999
020668	001	ENALAPRIL MALEATE;LEXXEL	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3		
			4703038	OCT 07, 2005	U-3		
020164	001	ENOXAPARIN SODIUM;LOVENOX				I-192	MAY 06, 2000
020444	001	EPOPROSTENOL SODIUM;FLOLAN	4335139	JUN 15, 1999			
			4539333	SEP 03, 2002			
			4883812	MAY 12, 2006	U-185		
			4338325	JUL 06, 1999			
020444	002	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002			
			4338325	JUL 06, 1999			
			4883812	MAY 12, 2006	U-185		
			4335139	JUN 15, 1999			
020417	001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007		NP	DEC 03, 1999
			5006342	APR 09, 2008			
020683	001	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000
020683	002	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000
019697	001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
019697	002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
018922	005	ETODOLAC;LODINE				I-24	JUN 28, 1999
020457	001	ETOPOSIDE PHOSPHATE;ETOPOPHOS	RE35524	AUG 04, 2007			
020410	001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171	NCE	DEC 06, 2001
			5219554	JUN 15, 2010			
			4827945	MAY 09, 2006	U-170		
			4951675	SEP 13, 2005	U-169		
			5055288	OCT 08, 2008			
			4695392	SEP 22, 2004			
			4695393	SEP 22, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			4770183	SEP 13, 2005	U-169		
020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192		
020038	001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
020235	003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
			4087544	JAN 16, 2000	U-86		
020622	001	GLATIRAMER ACETATE;COPAXONE				ODE	DEC 20, 2003
020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
019726	001	GOSERELIN ACETATE;ZOLADEX				I-191	JUN 27, 2000
020504	001	HYDROCHLOROTHIAZIDE;MICROZIDE				NS	DEC 27, 1999
020729	001	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
			4743450	FEB 24, 2007			
020729	002	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
			4743450	FEB 24, 2007			
020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
			5238944	AUG 24, 2010			
040024	001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
020083	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
020657	001	ITRACONAZOLE;SPORANOX				NDF	FEB 21, 2000
019927	001	KETOCONAZOLE;NIZORAL				I-186	MAY 30, 2000
020406	001	LANSOPRAZOLE;PREVACID				I-195	JUN 17, 2000
						I-196	MAY 08, 2000
						I-197	APR 17, 2000
						I-198	JUN 17, 2000
020406	002	LANSOPRAZOLE;PREVACID				I-195	JUN 17, 2000
						I-196	MAY 08, 2000
						I-197	APR 17, 2000
						I-198	JUN 17, 2000
020726	001	LETROZOLE;FEMARA				NCE	JUL 25, 2002
020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	4652411	NOV 01, 2004		NP	MAR 07, 2000
			4677191	JUL 03, 2005			
			4728721	MAY 01, 2006			
			4849228	JUL 18, 2006			
			4917893	NOV 01, 2004			
			4954298	NOV 01, 2004			
			5330767	NOV 01, 2004			
			5476663	APR 17, 2007			
			5480656	JAN 02, 2013			
			5575987	NOV 19, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4652441	NOV 01, 2004			
			5643607	JUL 01, 2014			
019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
			5480656	JAN 02, 2013			
			5643607	JUL 01, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5643607	JUL 01, 2014			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		5643607	JUL 01, 2014			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4677191	JUL 03, 2005		NS	MAY 30, 2000
		4728721	MAY 01, 2006		D-34	MAY 30, 2000
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652411	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
		5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020580 001	LIPASE;COTAZYM				NP	DEC 09, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010		NC	JUN 26, 2000
				5612054	SEP 28, 2010			
	020641	001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
	020704	001	LORATADINE;CLARITIN REDITABS	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
				4659716	APR 21, 2004	U-142		
>ADD>	019651	001	MESALAMINE;ASACOL				I-203	AUG 18, 2000
	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020689	001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
	020689	002	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
	020353	001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	020353	002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	020353	003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	019660	001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
	020778	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020779	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020636	001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
	020381	001	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	002	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	003	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	004	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	005	NIACIN;NIASPAN TITRATION STARTER PAC				NDF	JUL 28, 2000
	020714	001	NICOTINE;NICOTROL				NP	MAY 02, 2000
	020592	001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	4871865	OCT 03, 2006			
				4923892	MAY 08, 2007	U-174		
				5116863	MAY 26, 2009			
				5641805	JUN 24, 2014	U-184		
	019810	001	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
				5629305	FEB 04, 2014	U-188		
	019810	003	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
				5629305	FEB 04, 2014	U-188		
	020605	001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
				4695578	JUN 25, 2005	U-183		
				5578628	JUN 24, 2006	U-44		
>ADD>	019828	001	OXICONAZOLE NITRATE;OXISTAT				I-200	AUG 18, 2000
>ADD>	020262	001	PACLITAXEL;TAXOL	5641803	AUG 03, 2012	U-198	I-202	AUG 04, 2000
>ADD>							ODE	AUG 04, 2003
	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020031	003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAR 07, 1999
							NCE	DEC 29, 1997
	019385	001	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
				4180582	FEB 08, 1998	U-20		
	019385	002	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
				4180582	FEB 08, 1998	U-20		
	019385	003	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
				4180582	FEB 08, 1998	U-20		
	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
	020529	001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
				5057616	OCT 15, 2008			
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
>ADD>	020545	001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
>ADD>	020545	002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
	020701	001	PROGESTERONE;CRINONE				NP	JUL 31, 2000
	020701	002	PROGESTERONE;CRINONE				NP	JUL 31, 2000
	020756	001	PROGESTERONE;CRINONE				NP	MAY 13, 2000
	019627	002	PROPOFOL;DIPRIVAN				NP	JUN 11, 1999
	020559	001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U-186		
	020272	001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020588	001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014			
				5616587	JUN 11, 2014			
>ADD>	020659	001	RITONAVIR;NORVIR	5648497	JUL 15, 2014			
				5635523	JUN 03, 2014	U-190		
>ADD>	020680	001	RITONAVIR;NORVIR	5648497	JUL 15, 2014			
				5635523	JUN 03, 2014	U-190		
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012			
				5225445	FEB 12, 2008	U-182		
	020570	001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	020570	002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	019839	001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
	019839	002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
	019839	003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
	019839	004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019839	005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
	020231	001	SODIUM FLUORIDE;COLGATE TOTAL				NC	JUL 11, 2000
	019640	001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	019640	004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020168	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020168	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
>ADD>	020604	003	SOMATROPIN, BIOSYNTHETIC;SEROSTIM				NP	AUG 23, 1999
>ADD>	020626	001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
>ADD>	020626	002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
>ADD>	020626	003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
	020579	001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
				4731478	OCT 27, 2004			
				4703063	OCT 27, 2004			
				4772475	FEB 27, 2006			
	020600	001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
	020600	002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
	019785	003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA				I-190	MAY 23, 2000
	019057	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	020347	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
						U-165		
	020347	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020192	001	TERBINAFINE HYDROCHLORIDE;LAMISIL				I-180	JAN 21, 2000
	020707	001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
				4980171	APR 06, 2009			
	020676	001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
	020497	001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2004	U-196	NCE	MAY 29, 2002
							ODE	MAY 29, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020404	003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
				5045317	SEP 03, 2008	U-179		
	020475	001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
	074374	001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-189	JUN 17, 2000
	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
	020719	001	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
>ADD>				5104888	AUG 28, 2004		I-199	AUG 04, 2000
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		
	020719	002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
>ADD>				5104888	AUG 28, 2004		I-199	AUG 04, 2000
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		
>ADD>	020719	003	TROGLITAZONE;PRELAY	5457109	SEP 15, 2013	U-164	I-199	AUG 04, 2000
>ADD>				5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
>ADD>				5478852	SEP 15, 2013	U-163		
>ADD>				4572912	AUG 28, 2004			
>ADD>				5104888	AUG 28, 2004			
	020720	001	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164	NCE	JAN 29, 2002
>ADD>				5602133	SEP 15, 2013	U-173	I-199	AUG 04, 2000
				5478852	SEP 15, 2013	U-163		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
	020720	002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
>ADD>				4572912	AUG 28, 2004		I-199	AUG 04, 2000
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
>ADD>	020720	003	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164	I-199	AUG 04, 2000
>ADD>				5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
>ADD>				5478852	SEP 15, 2013	U-163		
>ADD>				4572912	AUG 28, 2004			
>ADD>				5104888	AUG 28, 2004			
	020617	001	UREA C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
	020617	002	UREA C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
	020665	001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020665	002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020547	001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189		
				5583152	AUG 22, 2006			
	020471	001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020458	001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004
	020458	002	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004

New 18th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 80128

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature) (11/97)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.